🔬 AACR 2026 Research Landscape

Example 1:

Abstract Number: 6519

Title: Abstract 6519: In silico discovery of fusion-specific RNA biomarkers in pediatric leukemias

DOI: https://doi.org/10.1158/1538-7445.am2026-6519

Abstract Preview: Abstract Purpose: Pediatric leukemia remains a leading cause of cancer-related mortality in children, with fusion-driven subtypes such as KMT2A-rearranged and ETV6-RUNX1 leukemias accounting for a significant proportion of high-risk cases. Despite improvements in overall survival, fusion-positive leukemias are associated with poorer outcomes, suboptimal therapeutic response, and elevated relapse r...

Example 2:

Abstract Number: 2474

Title: Abstract 2474: Non-completion of colorectal cancer screening among Alaska Native people in an intervention trial

DOI: https://doi.org/10.1158/1538-7445.am2026-2474

Abstract Preview: Abstract Background: The Alaska Tribal Health System is working to increase colorectal cancer (CRC) screening among Alaska Native peoples. It is unknown why people who initially agree to screening might not follow through to complete their screening. Methods: As part of a larger intervention investigating multi-target stool DNA (mt-sDNA) test use in rural Alaska communities, we interviewed Alaska ...

Example 3:

Abstract Number: 7837

Title: Abstract 7837: Enhanced sensitivity and scalability in liquid biopsy through integrated high-volume cfDNA extraction and droplet digital PCR mutation detection.

DOI: https://doi.org/10.1158/1538-7445.am2026-7837

Abstract Preview: Abstract Introduction: Detecting rare tumor-derived variants in plasma requires both efficient recovery of cell-free DNA (cfDNA) and highly quantitative mutation analysis. Conventional extraction methods are limited by low input capacity and potential bias toward longer fragments, which can compromise sensitivity for low-frequency alleles. Methods: Plasma cfDNA was extracted using the nRichDX Revo...

Example 4:

Abstract Number: 5523

Title: Abstract 5523: TNMplot 2.0: Stage-resolved and pan-cancer transcriptomic analytics for target discovery in oncology.

DOI: https://doi.org/10.1158/1538-7445.am2026-5523

Abstract Preview: Abstract BACKGROUND. TNMplot.com is a web-based resource that integrates RNA-Seq and gene-chip data from 56,938 samples, enabling differential gene expression analysis among normal, primary tumor, and metastatic tissues across 22 cancer types. Here, an updated version of the TNMplot database was established featuring new capabilities that advance pharmacological and translational oncology research...

Example 1:

Abstract Number: 6488

Title: Abstract 6488: Dual targeting of PARP and RAS enhances antitumor activity in pancreatic cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-6488

Abstract Preview: Abstract KRAS is the most frequent oncogenic mutation in PDAC. KRAS drives tumorigenesis and enhances mechanisms of DNA-damage repair (DDR). Specifically, KRAS upregulates HR and non-homologous end joining (NHEJ), which are critical pathways for DNA repair. Dual inhibition of these two driver pathways in BRCAmut PDAC, the MAPK/KRAS and the DDR, may have a promising therapeutic effect. However, thi...

Example 2:

Abstract Number: 2438

Title: Abstract 2438: Discovery of predictive circulating proteomic biomarkers for therapy response in HRR-driven solid tumors

DOI: https://doi.org/10.1158/1538-7445.am2026-2438

Abstract Preview: Abstract Background: The IMAGENE trial (jRCT2051210120) is a multicenter, tumor-agnostic, phase II basket study evaluating the combination of the PARP inhibitor niraparib and PD-1 inhibitors in patients with homologous recombination repair (HRR) gene mutations who have progressed following prior immune checkpoint inhibitor (ICI) therapy. In this tumor-agnostic setting, patients were enrolled with ...

Example 3:

Abstract Number: 7854

Title: Abstract 7854: Prognostic impact of gain-of-function TP53 mutations on outcomes in HER2-negative advanced gastric cancer.

DOI: https://doi.org/10.1158/1538-7445.am2026-7854

Abstract Preview: Abstract Background: TP53 alterations are among the most prevalent genomic events across solid tumors, yet the biological and clinical heterogeneity of TP53 mutation types—particularly gain-of-function (GOF) variants—remains poorly defined in advanced gastric cancer (AGC). GOF mutations involving the DNA-binding domain can confer oncogenic properties beyond simple loss of tumor suppressor activity...

Example 4:

Abstract Number: 5546

Title: Abstract 5546: Rilvegostomig elicits greater immune activation and tumor inhibition than clinically approved anti-PD-1 monotherapy in models of HNSCC

DOI: https://doi.org/10.1158/1538-7445.am2026-5546

Abstract Preview: Abstract Background: Rilvegostomig (AZD2936) is a monovalent, bispecific humanized IgG1 monoclonal antibody that targets human TIGIT and PD-1, engineered with a triple-mutation in its fragment crystallizable (Fc)-domain to prevent Fc-effector functionality. Rilvegostomig has shown promising anti-tumor activity in NSCLC patients in a Phase I/II clinical trial (NCT04995523) and is currently being in...

Example 1:

Abstract Number: 5942

Title: Abstract 5942: Longitudinal liquid biopsy profiling in breast cancer patient: Clinical utility and guidelines

DOI: https://doi.org/10.1158/1538-7445.am2026-5942

Abstract Preview: Abstract Background: The clinical impact of repeated liquid biopsies in metastatic breast cancer have not been fully established. While circulating tumor DNA (ctDNA) profiling provides actionable insights, its value after an initially positive test is uncertain. We evaluated the clinical relevance of serial ctDNA analyses according to the initial biopsy result. Methods: Patients from the prospecti...

Example 2:

Abstract Number: 2107

Title: Abstract 2107: Genomic landscape of melanoma brain metastases: Real-world analysis and comparison with public melanoma cohorts.

DOI: https://doi.org/10.1158/1538-7445.am2026-2107

Abstract Preview: Abstract Background: Melanoma brain metastases (MBM) represent a biologically distinct and clinically aggressive subset of melanoma. Comprehensive molecular characterization focused on intracranial disease remains limited. We aimed to define the genomic landscape of MBM and compare these findings with public melanoma datasets. Methods: We retrospectively identified 166 patients with histologically...

Example 3:

Abstract Number: 7840

Title: Abstract 7840: Evaluation of somatic mutations in cell-free DNA as noninvasive biomarkers of cancer in asymptomatic pregnant women.

DOI: https://doi.org/10.1158/1538-7445.am2026-7840

Abstract Preview: Abstract Prenatal cell-free (cf) DNA sequencing for fetal aneuploidy incidentally detects circulating tumor DNA in the plasma of asymptomatic pregnant women. Distinguishing the subset of women with malignant tumors detected by prenatal sequencing from those with benign conditions, such as uterine fibroids, is critical to maternal medical management. In this pilot study, prospectively collected blo...

Example 4:

Abstract Number: 5115

Title: Abstract 5115: A multi-omic liquid biopsy for the earlier detection of colorectal cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5115

Abstract Preview: Abstract Background: Timely diagnosis and intervention in colorectal cancer (CRC) are critical to improving patient outcomes and limiting disease progression. Screening of average-risk individuals is essential for detecting tumors at an earlier, more treatable stage. However, adherence to current screening programs remains suboptimal. Liquid biopsies represent a promising alternative to stool-base...

Example 1:

Abstract Number: 6514

Title: Abstract 6514: Detection of bladder cancer in patients with microscopic hematuria using Oncuria-Detect, interim analysis of an international prospective study

DOI: https://doi.org/10.1158/1538-7445.am2026-6514

Abstract Preview: Abstract Background- Microscopic hematuria occurs in up to 10% of the general population and initiates costly evaluation to ensure no bladder cancer exists. Oncuria-Detect is a 10-plex immunoassay that detects de novo bladder cancer by generating a protein biomarker signature from a single voided urine sample. This report details the interim analysis of our prospective study that compares the diag...

Example 2:

Abstract Number: 2570

Title: Abstract 2570: Reprogramming T-cell networks to overcome immune evasion in ovarian cancer relapse

DOI: https://doi.org/10.1158/1538-7445.am2026-2570

Abstract Preview: Abstract Ovarian cancer (OC) remains a major clinical challenge due to its high recurrence rates and resistance to standard therapies. High-grade serous ovarian cancer (HGSOC), the most common and aggressive OC subtype, often presents with tumor-infiltrating lymphocytes (TILs), yet immune checkpoint blockade (ICB) therapies have shown limited efficacy. Our studies aim to dissect the spatiotemporal...

Example 3:

Abstract Number: 7840

Title: Abstract 7840: Evaluation of somatic mutations in cell-free DNA as noninvasive biomarkers of cancer in asymptomatic pregnant women.

DOI: https://doi.org/10.1158/1538-7445.am2026-7840

Abstract Preview: Abstract Prenatal cell-free (cf) DNA sequencing for fetal aneuploidy incidentally detects circulating tumor DNA in the plasma of asymptomatic pregnant women. Distinguishing the subset of women with malignant tumors detected by prenatal sequencing from those with benign conditions, such as uterine fibroids, is critical to maternal medical management. In this pilot study, prospectively collected blo...

Example 4:

Abstract Number: 5465

Title: Abstract 5465: Improving early cancer detection by training scalable deep neural networks to extract tumor signal from cell-free DNA.

DOI: https://doi.org/10.1158/1538-7445.am2026-5465

Abstract Preview: Abstract Introduction: Blood-based liquid biopsies offer potential for non-invasive cancer screening. However, detecting early-stage disease is complicated by low levels of circulating tumor biomarkers and background noise from normal cells. To address this, we developed a novel deep-learning framework to detect cancer signal at the resolution of single DNA reads. Applied to bisulfite-converted ce...

Example 1:

Abstract Number: 6377

Title: Abstract 6377: Intranasal delivery of lipid-based nanoparticle encapsulating CXCR7 agonist improves PD-L1 blockade efficacy in glioblastoma.

DOI: https://doi.org/10.1158/1538-7445.am2026-6377

Abstract Preview: Abstract Background Glioblastoma (GBM) is characterized by limited treatment options and poor survival outcomes. Glioblastoma-associated macrophages (GAMs) are crucial factors that tailor the immunosuppressive tumor microenvironment (TME). Our previous study revealed that VUF11207 (VUF), a CXCR7 agonist, effectively recaptured the efficacy of the anti-PD-L1 antibody (αPD-L1) in GBM-bearing mice th...

Example 2:

Abstract Number: 2508

Title: Abstract 2508: New precision treatments for glioblastoma

DOI: https://doi.org/10.1158/1538-7445.am2026-2508

Abstract Preview: Abstract The main goal of this study is to develop precision treatments for glioblastoma (GBM). GBM is a deadly brain tumor with few treatment options, mainly due to high intra- and inter-tumoral heterogeneity manifested by diverse genetic alterations and cellular components within an individual tumor or among different patients. Previous efforts targeting molecular features have focused on three ...

Example 3:

Abstract Number: 7815

Title: Abstract 7815: Efficacy of ABBV-706, a SEZ6-targeted topoisomerase 1 inhibitor ADC: A report from the Pediatric Preclinical In Vivo Testing (PIVOT) Program

DOI: https://doi.org/10.1158/1538-7445.am2026-7815

Abstract Preview: Abstract Introduction: ABBV-706 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting the seizure-related homolog 6 (SEZ6) surface protein linked to topoisomerase 1 inhibitor payload. A Phase 1 trial of ABBV-706 is underway in adults with SEZ6 expressing relapsed solid tumors (NCT05599984). ABBV-706 became of interest as SEZ6 is highly expressed in many pediatric cancers....

Example 4:

Abstract Number: 5545

Title: Abstract 5545: Collagen-binding anti-GITR antibody reshapes immunosuppressive microenvironment and prolongs survival in recurrent glioblastoma

DOI: https://doi.org/10.1158/1538-7445.am2026-5545

Abstract Preview: Abstract Recurrent glioblastoma (rGBM) remains lethal with median survival under six months, due to immunotherapy resistance driven by immunosuppressive tumor microenvironment (TME) with elevated regulatory T cells (Tregs). Despite the development of Treg-targeting antibodies such as anti-GITR (Glucocorticoid-induced TNFR-related protein) antibody, their poor delivery to brain tumors has restricte...

Example 1:

Abstract Number: 6278

Title: Abstract 6278: Unraveling the missing heritability of unexplained familial cancers with germline genome sequencing.

DOI: https://doi.org/10.1158/1538-7445.am2026-6278

Abstract Preview: Abstract While established predisposition genes account for syndromes like Cowden and Lynch syndrome, cancers frequently cluster in families without any identifiable pathogenic variant (PGV). We hypothesized that other germline factors beyond established PGVs might partially explain the large fraction of familial cancer cases with no known PGV. In this study, we systematically assessed potential g...

Example 2:

Abstract Number: 2247

Title: Abstract 2247: Intracellular complement signaling plays a critical role in s1p/s1pr1 mediated inflammasome activation and tumor metastasis.

DOI: https://doi.org/10.1158/1538-7445.am2026-2247

Abstract Preview: Abstract Sphingolipid metabolism, specifically sphingosine 1-phosphate (S1P), has been demonstrated to regulate cancer progression and metastasis. Our previous research showed that oncogenic S1P and S1P receptor 1 (S1PR1) signaling activated intracellular C3 complement processing to enhance migration/metastasis through inflammasome activation by the C3-PPIL1 complex. This study addressed how the S...

Example 3:

Abstract Number: 7854

Title: Abstract 7854: Prognostic impact of gain-of-function TP53 mutations on outcomes in HER2-negative advanced gastric cancer.

DOI: https://doi.org/10.1158/1538-7445.am2026-7854

Abstract Preview: Abstract Background: TP53 alterations are among the most prevalent genomic events across solid tumors, yet the biological and clinical heterogeneity of TP53 mutation types—particularly gain-of-function (GOF) variants—remains poorly defined in advanced gastric cancer (AGC). GOF mutations involving the DNA-binding domain can confer oncogenic properties beyond simple loss of tumor suppressor activity...

Example 4:

Abstract Number: 5308

Title: Abstract 5308: Monitoring treatment response in metastatic breast cancer patients using an mDETECT assay.

DOI: https://doi.org/10.1158/1538-7445.am2026-5308

Abstract Preview: Abstract Metastatic breast cancer treatment response is currently monitored with CT-scans every 3-6 months leaving many patients on ineffective therapy while their disease progresses. We have developed the methylation DETEction of Circulating Tumour DNA (mDETECT) assay, a targeted DNA methylation-based Next Generation Sequencing liquid biopsy designed to detect cancer specific DNA methylation patt...

Example 1:

Abstract Number: 6331

Title: Abstract 6331: A translational framework for high-plex spatial profiling and complexity reduction toward diagnostic assay development in colorectal polyps

DOI: https://doi.org/10.1158/1538-7445.am2026-6331

Abstract Preview: Abstract Background: Accurate risk stratification of colorectal polyps is essential for reducing unnecessary surveillance while ensuring that high-risk patients receive timely intervention. Pathology workflows rely on morphology from H&E slides, while emerging immune-profiling techniques such as multiplex immunofluorescence (mIF) offer deeper biological resolution but are often too complex and...

Example 2:

Abstract Number: 2799

Title: Abstract 2799: Tumoral IL-33/ST2 signaling drives immune escape through reduced antigen presentation

DOI: https://doi.org/10.1158/1538-7445.am2026-2799

Abstract Preview: Abstract The majority (up to 85%) of colorectal cancer (CRC) patients have a microsatellite stable (MSS) tumor phenotype, which is a poor responder to immune checkpoint blockade (ICB). Therefore, there is a need to identify novel checkpoints in the tumor microenvironment, such as ST2 (Stimulation 2, IL33 receptor). We demonstrated ST2 to be prominently expressed on human tumor cells, especially MS...

Example 3:

Abstract Number: 7820

Title: Abstract 7820: CHIP detection in solid tumors differs between liquid biopsy testing approaches.

DOI: https://doi.org/10.1158/1538-7445.am2026-7820

Abstract Preview: Abstract Objective: Clonal hematopoiesis of indeterminate potential (CHIP) arises from somatic variants in hematopoietic progenitor cells and is more frequent in older individuals. CHIP can appear as incidental findings in cell-free DNA (cfDNA) from patients with solid tumors, introducing biological background noise that may confound result interpretation. MSK-ACCESS® powered with SOPHiA DDM™ inco...

Example 4:

Abstract Number: 5471

Title: Abstract 5471: Genie-ADLA: A deep learning algorithm for methylation-based multiple cancer early detection (MCED).

DOI: https://doi.org/10.1158/1538-7445.am2026-5471

Abstract Preview: Abstract Background: Methylation-based analysis of cell-free DNA (cfDNA) has emerged as a key technology for MCED. However, existing approaches rely on traditional machine learning algorithms, which inherently limit detection performance. With the rapid advancement of artificial intelligence (AI), we have developed Genie-ADLA, a deep learning algorithm designed specifically for MCED. By integratin...

Example 1:

Abstract Number: 6352

Title: Abstract 6352: Strengthening guideline compliant care delivery in a safety net hospital through artificial intelligence (AI) enabled technology solutions

DOI: https://doi.org/10.1158/1538-7445.am2026-6352

Abstract Preview: Abstract Background: Concordance with guideline-based cancer care is often low in resource-constrained settings, leading to under- or over-treatment and delays in care. Navya Earthshot is a validated AI-enabled decision support system that matches patient records to standard-of-care cancer treatment guidelines to generate evidence-based recommendations. This study evaluated the implementation of N...

Example 2:

Abstract Number: 2475

Title: Abstract 2475: Resource limitations and cancer care access for Native Hawaiian/Pacific Islander veterans in the Pacific region

DOI: https://doi.org/10.1158/1538-7445.am2026-2475

Abstract Preview: Abstract Native Hawaiian/Pacific Islander (NHPI) populations may experience poorer cancer-related outcomes, shaped by social determinants such as higher poverty rates and underrepresentation in national data. NHPI Veterans face heightened vulnerability due to military-related exposures and the need to navigate distinct Veterans Health Administration (VHA) pathways for care, adding complexity not e...

Example 3:

Abstract Number: 7866

Title: Abstract 7866: BMI- and subtype-specific molecular clusters reveal distinct obesity mechanisms in breast cancer across Nigerian and U.S. cohorts.

DOI: https://doi.org/10.1158/1538-7445.am2026-7866

Abstract Preview: Abstract Background: Obesity is a major breast cancer risk factor, yet its biological mechanisms remain poorly characterized in African populations. We hypothesized that distinct obesity-associated molecular signatures would differentiate obese from normal-weight Nigerian women and reveal subtype-specific patterns in U.S. women. Methods: Targeted gene expression profiling (NanoString, 785 genes) w...

Example 4:

Abstract Number: 5489

Title: Abstract 5489: Multi-scale foundational AI descriptors enable accurate tumor localization in digitized renal cell carcinoma pathology.

DOI: https://doi.org/10.1158/1538-7445.am2026-5489

Abstract Preview: Abstract Background: Renal cell carcinoma (RCC) diagnosis relies on accurate tumor localization on pathology whole slide images, but suffers from substantial inter-observer variability, which can impact treatment selection. Recent advances in digital pathology AI tools have resulted in foundation models (FMs) that are trained on diverse H&E images to learn patterns of tissue morphology. Howeve...

Example 1:

Abstract Number: 5977

Title: Abstract 5977: mTOR inhibition activates the EGFR-MAPK network by a novel AKT-initiated feedback loop promoting adaptive resistance

DOI: https://doi.org/10.1158/1538-7445.am2026-5977

Abstract Preview: Abstract Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally, resulting in more than 300,000 deaths each year worldwide. Treatment options for HNSCC patients include surgery, radiation, chemotherapy, and molecularly targeted therapies, and although immunotherapies have recently revolutionized the treatment landscape, <20% of HNSCC patients respond to immun...

Example 2:

Abstract Number: 2615

Title: Abstract 2615: Diffusion kurtosis imaging to predict tumor hypoxia and recurrence in HPV-associated oropharyngeal cancer.

DOI: https://doi.org/10.1158/1538-7445.am2026-2615

Abstract Preview: Abstract Introduction: A recent phase II trial demonstrated the efficacy of hypoxia-guided chemoradiation (CRT) de-escalation in human papillomavirus-associated oropharyngeal cancer (HPV+ OPC). 18F-fluoromisonidazole (18F-FMISO) positron emission tomography (PET), used to measure hypoxia, is not widely available, limiting use of hypoxia as an imaging biomarker in research and clinical care. Diffus...

Example 3:

Abstract Number: 7773

Title: Abstract 7773: Continuation of immune checkpoint inhibitor therapy after progression in head and neck squamous cell carcinoma: A multicenter study

DOI: https://doi.org/10.1158/1538-7445.am2026-7773

Abstract Preview: Abstract Background: Immune checkpoint inhibitors (ICIs) have significantly improved survival outcomes in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, disease progression after first-line ICI therapy remains a major clinical challenge, and the benefit of ICI continuation or rechallenge after progression has not been fully elucidated. Methods: In this multicenter ...

Example 4:

Abstract Number: 5356

Title: Abstract 5356: Leveraging a real-world clinicogenomic database for post-sequencing quality assessment in solid tumor comprehensive genomic profiling (CGP).

DOI: https://doi.org/10.1158/1538-7445.am2026-5356

Abstract Preview: Abstract The quantity and integrity of DNA and RNA extracted from formalin-fixed paraffin-embedded (FFPE) tumor specimens can vary significantly due to factors such as block age, fixation conditions, protein crosslinking, and the presence of chemical inhibitors. Over a decade of research has demonstrated that, with optimized pre- and post-analytical workflows, FFPE samples can serve as reliable in...

Example 1:

Abstract Number: 6407

Title: Abstract 6407: Deep learning-driven image analysis for tracking nucleolar morphology

DOI: https://doi.org/10.1158/1538-7445.am2026-6407

Abstract Preview: Abstract Introduction: The nucleolus, a membraneless nuclear organelle responsible for ribosome production, is highly sensitive to stress. A subset of chemotherapeutic drugs induce nucleolar stress, which could influence their apoptotic mechanisms. However, tracking morphological changes of the nucleolus during treatment remains challenging due to its amorphic state and nanoscale organization. A m...

Example 2:

Abstract Number: 2478

Title: Abstract 2478: Advancing equitable preventative cancer screening on the Inova Saville mobile health bus

DOI: https://doi.org/10.1158/1538-7445.am2026-2478

Abstract Preview: Abstract Purpose: The INOVA Saville Mobile Health Bus (SMHB), launched in January 2025, aims to expand access to breast and cervical cancer screenings and novel research trials among medically underserved communities in Northern Virginia. Using de-identified, aggregated data, this analysis assessed early program reach, identified race/ethnic and geographic gaps in utilization, and used these insig...

Example 3:

Abstract Number: 7831

Title: Abstract 7831: Diagnostic genomics in retinoblastoma: Aqueous humor outperforms blood for tumor-specific insights.

DOI: https://doi.org/10.1158/1538-7445.am2026-7831

Abstract Preview: Abstract Purpose: There remains controversy in ocular oncology over whether blood or AH is a superior liquid biopsy for retinoblastoma (RB). Herein, we compare their diagnostic utility. Methods: Matched AH and plasma were collected at diagnosis from 13 patients (16 eyes) with RB. Cell-free DNA was sequenced to assess copy number alteration (CNA) amplitude; ichorCNA software was used to estimate tu...

Example 4:

Abstract Number: 5499

Title: Abstract 5499: SpatialTopic exploring tumor ecosystem in 3D multiplexed imaging of melanoma.

DOI: https://doi.org/10.1158/1538-7445.am2026-5499

Abstract Preview: Abstract Background: Advances in multiplexed imaging now profile cell phenotypes from 2D to 3D, creating new opportunities to analyze spatial organization in complex tissue. A 3D view of tissue architecture enables a re-examination of tumor-immune interactions in the tumor microenvironment, revealing spatially organized niches with direct biological and clinical relevance that may be obscured in 2...

Example 1:

Abstract Number: 6547

Title: Abstract 6547: Phase II single arm study of tremelimumab and durvalumab (MEDI4736) (T300+D) in advanced hepatocellular carcinomas with Child-Pugh-B cirrhosis (STRIDE in CP-B)

DOI: https://doi.org/10.1158/1538-7445.am2026-6547

Abstract Preview: Abstract Background: In registration phase 3 studies, most patients enrolled had Child-Pugh (CP)-A cirrhosis, with CP-B cirrhosis are often excluded from clinical trials, yet in clinical practices, patients are often treated with new agents without efficacy or safety data. Therefore, there is an unmet need to evaluate the efficacy and safety of therapeutics in patients with HCC and CP-B cirrhosis....

Example 2:

Abstract Number: 2611

Title: Abstract 2611: Prospective evaluation of 68Ga-PSMA PET imaging in advanced hepatocellular carcinoma patients undergoing first line immunotherapy.

DOI: https://doi.org/10.1158/1538-7445.am2026-2611

Abstract Preview: Abstract Prostate-specific membrane antigen (PSMA) is highly expressed in tumor-associated neovasculature in hepatocellular carcinoma (HCC), highlighting its promise as a theranostic target. This prospective study aimed to evaluate the utility of novel biomarkers derived from PSMA positron emission tomography computed tomography (PET/CT) to assess treatment response in advanced HCC patients (pts) ...

Example 3:

Abstract Number: 7860

Title: Abstract 7860: Fusion gene machine learning models improve clinical outcome prediction of hepatocellular carcinoma.

DOI: https://doi.org/10.1158/1538-7445.am2026-7860

Abstract Preview: Abstract Hepatocellular carcinoma is one of the most lethal malignancies for humans. Assessing the clinical outcomes of HCC remains challenging. In this study, we analyzed a panel of 20 fusion genes in 200 hepatocellular carcinoma (HCC) samples to predict the recurrence and survival rates of HCC patients undergoing surgical interventions using machine learning models. The results showed that fusio...

Example 4:

Abstract Number: 5677

Title: Abstract 5677: GPX4-FTH1-ARNT signaling regulates iron efflux to suppress ferroptotic cell death and promote immune remodeling in osteosarcoma.

DOI: https://doi.org/10.1158/1538-7445.am2026-5677

Abstract Preview: Abstract Osteosarcoma is the leading primary malignant bone tumor in children and young adults. Despite multimodal therapy involving surgery and multi-agent chemotherapy, patient survival rates have remained stagnant over the past four decades, necessitating the development of novel, effective therapeutic strategies. Ferroptosis, an iron-dependent programmed cell death, is a promising therapeutic ...

Example 1:

Abstract Number: 6473

Title: Abstract 6473: Clonal consolidation and transcriptional re-programming define non-small cell lung cancers resistant to immune checkpoint inhibitors

DOI: https://doi.org/10.1158/1538-7445.am2026-6473

Abstract Preview: Abstract Analysis of pre-treatment non-small cell lung cancers (NSCLCs) has helped identify predictors of response to immune checkpoint inhibitors (ICI), including low PD-L1 expression, targetable drivers alterations (EGFR, ALK), and STK11/KEAP1 mutations. To-date, however, few samples at treatment resistance have been studied, and consequently less is known about the mechanisms contributing to IC...

Example 2:

Abstract Number: 2593

Title: Abstract 2593: Enspyre MRD: Validation of an ultra-sensitive kitted MRD solution at low sequencing depth

DOI: https://doi.org/10.1158/1538-7445.am2026-2593

Abstract Preview: Abstract Detection of MRD post surgery and monitoring of ctDNA during treatment are gaining increasing traction in patient care and drug development. First-generation assays have considerable clinical datasets, but suffer from limited sensitivity due to low numbers of mutations tracked. Recent ‘ultra-sensitive’ solutions detect ctDNA at <100 parts per million (ppm), but suffer from high seq...

Example 3:

Abstract Number: 7778

Title: Abstract 7778: GS24-B047, a potential best-in-class DLL3-targeting T-cell engager with integrated costimulatory signal, for the treatment of small cell lung cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-7778

Abstract Preview: Abstract Background: Small cell lung cancer (SCLC) remains an aggressive malignancy with limited therapeutic options and poor prognosis, particularly in the relapsed/refractory settings. DLL3, a tumor-associated antigen highly expressed on SCLC cells with minimal expression in normal tissues, represents a promising therapeutic target. While T-cell engagers (TCEs) targeting DLL3 and CD3, such as Ta...

Example 4:

Abstract Number: 5590

Title: Abstract 5590: BCG024: A novel DLL3×CD3×4-1BB trispecific T cell engager enhances T cell persistence and functionality in preclinical models

DOI: https://doi.org/10.1158/1538-7445.am2026-5590

Abstract Preview: Abstract Background: CD3-based T cell engagers (TCEs) as powerful therapeutic agents have demonstrated clinical success in both hematologic malignancies and solid tumor indications. One major obstacle to TCE therapies in treating solid tumors is T-cell exhaustion due to conventional TCEs lacking co-stimulatory signaling, limiting their therapeutic durability. To address this challenge, integrating...

Example 1:

Abstract Number: 6544

Title: Abstract 6544: Immune checkpoint inhibitor therapy in kidney transplant recipients: Real-world outcomes of antitumor activity and graft rejection risk

DOI: https://doi.org/10.1158/1538-7445.am2026-6544

Abstract Preview: Abstract Background: Kidney transplant recipients (KTRs) have a markedly elevated risk of aggressive malignancies, yet the use of immune checkpoint inhibitors (ICIs) in this population remains limited by concerns for allograft rejection and the absence of prospective evidence. We evaluated real-world antitumor activity, graft safety, and immunosuppression-related outcomes of ICI therapy in KTRs wi...

Example 2:

Abstract Number: 2578

Title: Abstract 2578: Clinical feasibility study of Optim.AI 2.0, a co-culture high-content functional precision platform for predicting combinatorial immunotherapy response

DOI: https://doi.org/10.1158/1538-7445.am2026-2578

Abstract Preview: Abstract Background: Immunotherapies have advanced cancer treatment, but variable outcomes and the lack of robust predictive biomarkers limit their use. Better patient selection and rational combination strategies could expand their effectiveness. Optim.AI™ is a combinatorial functional precision medicine platform previously shown to identify effective combination treatments for hematologic cancer...

Example 3:

Abstract Number: 7883

Title: Abstract 7883: Surface CADM1 (Cell Adhesion Molecule 1) abundance predicts payload delivery and in-vitro efficacy of CADM1-GGFG-Exatecan ADC in osteosarcoma, aiding optimal candidate selection

DOI: https://doi.org/10.1158/1538-7445.am2026-7883

Abstract Preview: Abstract Background: ADC development in osteosarcoma has been hindered by the absence of effective, targetable surface antigens. We previously identified CADM1, a cell-surface adhesion molecule, as a promising therapeutic target and generated three CADM1-directed ADCs (CADM1-Tesirine, CADM1-PEG-Exatecan, and CADM1-GGFG-Exatecan) with distinct linker-payload combinations. To select the optimal cand...

Example 4:

Abstract Number: 5783

Title: Abstract 5783: HY809382, a PRC2 degrader with best-in-class properties, demonstrates efficacy across multiple tumors and overcomes EZH2 inhibitor clinical resistance caused by EZH2 genetic mutations

DOI: https://doi.org/10.1158/1538-7445.am2026-5783

Abstract Preview: Abstract The dysregulation of Polycomb repressive complex 2 (PRC2) is implicated in tumorigenesis across a spectrum of cancers, such as prostate cancer, non-small cell lung cancer, ​endometrial carcinoma, ovarian cancer, clear cell renal cell carcinoma and hematological malignancies. Furthermore, aberrant PRC2 activity is closely associated with tumor immune evasion and the development of therapy ...

Example 1:

Abstract Number: 6461

Title: Abstract 6461: Comprehensive cytokine, chemokine and immune marker evaluation in plasma samples of primary, non-metastatic high grade serous ovarian cancer patients to estimate outcome and platinum resistance

DOI: https://doi.org/10.1158/1538-7445.am2026-6461

Abstract Preview: Abstract Background: Ovarian cancer (OC) still has the highest mortality rate of all gynecological malignancies, diagnosed mostly at advanced stages, resulting in a generally poor outcome. Radical tumor debulking, followed by platinum-based chemotherapy with/without bevacizumab and with/without PARP inhibitors is the standard of care in advanced OC. However, the majority of patients will ultimatel...

Example 2:

Abstract Number: 2257

Title: Abstract 2257: Eric Medina.

DOI: https://doi.org/10.1158/1538-7445.am2026-2257

Abstract Preview: Abstract Most high-grade serous carcinomas are thought to originate from the fallopian tube epithelium and progress through pre-malignant states that are more susceptible to transformation in BRCA1/2 mutation carriers. However, the early epithelial and stromal programs that arise during transformation remain poorly defined. To address this gap, we analyzed 49 FFPE scRNA-seq samples from 28 patient...

Example 3:

Abstract Number: 7749

Title: Abstract 7749: Increased immune activity in patients with high-grade serious ovarian cancer after combination PARPi + ATRi therapy

DOI: https://doi.org/10.1158/1538-7445.am2026-7749

Abstract Preview: Abstract Introduction: Complete responses to PARP inhibitor (PARPi) monotherapy in recurrent high-grade serous ovarian cancer (HGSOC) are rare. However, preclinical data have demonstrated promising synergy between PARP and ATR inhibitors. Characterizing the immune contexture of the tumor microenvironment and the surrounding stroma during treatment may provide valuable biological insights into the ...

Example 4:

Abstract Number: 5626

Title: Abstract 5626: Combination epigenetic therapy unmasks non-canonical neoantigens to improve adoptive T cell therapy in ovarian cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5626

Abstract Preview: Abstract Immunotherapy has revolutionized cancer treatment across a range of malignancies, yet its efficacy in ovarian cancer (OC) has remained limited due to low tumor mutational burden and limited neoantigen availability. While current immunotherapy strategies have struggled to achieve durable responses, adoptive T cell therapy (ATT) combined with epigenetic therapies that expand the antigenic l...

Example 1:

Abstract Number: 6497

Title: Abstract 6497: Synergistic disruption of KRAS and FAK pathways: A preclinical pipeline for PDAC therapy optimization

DOI: https://doi.org/10.1158/1538-7445.am2026-6497

Abstract Preview: Abstract Background: KRAS mutations are among the most prevalent oncogenic drivers across solid tumors, with particularly high incidence in Pancreatic Ductal Adenocarcinoma (PDAC). Despite their clinical relevance, direct targeting of KRAS has historically been difficult. The advent of KRAS G12C-specific inhibitors has marked a breakthrough in targeted therapy, yet acquired resistance remains a ma...

Example 2:

Abstract Number: 2543

Title: Abstract 2543: Serum calreticulin as a promising biomarker for cancer screening

DOI: https://doi.org/10.1158/1538-7445.am2026-2543

Abstract Preview: Abstract Background: Calreticulin (CALR) is an endoplasmic reticulum chaperone protein that can translocate to the plasma membrane during cellular stress. Despite its known roles in cancer, CALR levels in the blood have not been extensively studied in cancer patients. We hypothesized that serum CALR is elevated in cancer patients and may serve as a noninvasive biomarker for early detection. Method...

Example 3:

Abstract Number: 7754

Title: Abstract 7754: Peripheral immune signatures associated with peptide receptor radionuclide therapy in neuroendocrine tumors

DOI: https://doi.org/10.1158/1538-7445.am2026-7754

Abstract Preview: Abstract Background: Peptide receptor radionuclide therapy (PRRT) is an internal radiotherapy for somatostatin receptor (SSTR)-positive neuroendocrine tumor (NET). The tumor microenvironment, particularly cytotoxic T lymphocyte (CTL), is a key determinant of tumor behavior, treatment response, and prognosis, but NET typically shows a “cold” immune microenvironment with sparse immune-cell infiltrat...

Example 4:

Abstract Number: 5769

Title: Abstract 5769: A potent TOP2 poison with robust preclinical efficacy and a favorable therapeutic window supporting clinical evaluation in pancreatic cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5769

Abstract Preview: Abstract Background. Topoisomerase 2 alpha ( TOP2A) is overexpressed in pancreatic ductal adenocarcinoma (PDAC) and its expression strongly correlates with poor prognosis and increased metastatic potential. Several TOP2A targeting drugs, including doxorubicin (DOX) are available, but none represent effective PDAC treatment modalities. Annamycin (ANN), a potent, non-cardiotoxic analog of DOX, but i...

Example 1:

Abstract Number: 6289

Title: Abstract 6289: Targeted sequencing of common cancer susceptibility genes reveals germline variants in African prostate cancer patients.

DOI: https://doi.org/10.1158/1538-7445.am2026-6289

Abstract Preview: Abstract Background: Prostate cancer (PCa) is the leading cause of cancer-related deaths globally and disproportionately affects men of African ancestry. African men often present at younger ages and with more aggressive disease, and approximately half of the PCa risk has been attributed to genetic factors. Africa is the most genetically diverse region of the world, and even within the continent, ...

Example 2:

Abstract Number: 2483

Title: Abstract 2483: Survivorship and sexual health: What we learned from Black men in community town halls

DOI: https://doi.org/10.1158/1538-7445.am2026-2483

Abstract Preview: Abstract Background: Prostate cancer (CaP) is among the most common cancers in U.S. men, with Black men experiencing a 1.7-fold higher incidence and nearly twice the mortality rate compared with non-Hispanic White men. While early detection has improved survival, differences remain in recovery and quality of life (QoL). Sexual dysfunction after treatment affects identity, relationships, and well-b...

Example 3:

Abstract Number: 7725

Title: Abstract 7725: Integrative molecular profiling identifies predictors of response to sacituzumab govitecan in advanced prostate cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-7725

Abstract Preview: Abstract Prostate cancer is the second leading cause of cancer related death in men. Potent therapies that inhibit the androgen receptor (AR) transcription factor have improved survival of patients with prostate cancer, however many cases progress to lethal castration resistant prostate cancer (CRPC). Resistance to AR-targeted therapies is frequently mediated by reactivation of AR signaling or tra...

Example 4:

Abstract Number: 5430

Title: Abstract 5430: Allostatic load connects tumor genomics, disease trajectory, and pre-diagnosis wearable activity.

DOI: https://doi.org/10.1158/1538-7445.am2026-5430

Abstract Preview: Abstract Background: Allostatic load (AL), a composite index of physiological stress from routine labs and vitals, reflects multisystem strain and predicts survival in cancer. Building on prior validation of cancer-modulated AL (cmAL), we examined how cmAL varies across disease states, relates to tumor genomics, and aligns with wearable-measured activity before diagnosis. Methods: We analyzed 12,6...

Example 1:

Abstract Number: 6459

Title: Abstract 6459: Development of FL115, a novel IL-15 superagonist, as subcutaneous injection for cancer immunotherapy

DOI: https://doi.org/10.1158/1538-7445.am2026-6459

Abstract Preview: Abstract Background: FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein, in which Fbody is a single-chain Fc designed to eliminate classical Fc effects including ADCC/CDC/ADCP while retaining FcRn engagement. In Phase I clinical studies in patients with advanced solid tumors, FL115 administered as weekly IV infusion (dose range: 3-90 μg/kg) demonstrated favorable safety profile and prelimina...

Example 2:

Abstract Number: 2678

Title: Abstract 2678: A multimodal model to forecast prostate cancer metastasis from primary tumor transcriptomics and histopathology morphology.

DOI: https://doi.org/10.1158/1538-7445.am2026-2678

Abstract Preview: Abstract Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous malignancies in men in the United States, and metastatic dissemination remains the principal driver mortality. While advanced disease is typically managed with androgen deprivation therapy, most patients eventually progress to castration-resistant PCa, underscoring the need for early identification of tumors predisposed to...

Example 3:

Abstract Number: 7862

Title: Abstract 7862: Population analysis and immunologic landscape of melanoma in people living with HIV.

DOI: https://doi.org/10.1158/1538-7445.am2026-7862

Abstract Preview: Abstract Purpose: To dissect the clinical and immunological features of people living with HIV (PLWH) diagnosed with melanoma, who have consistently shown worse outcomes than HIV-negative individuals (PLw/oH) with the same cancer. Experimental Design: We analyzed electronic health records from 1,087 PLWH and 394,437 PLw/oH with melanoma. Demographic and clinical characteristics were compared. Spat...

Example 4:

Abstract Number: 5421

Title: Abstract 5421: Determining the benefit of comprehensive molecular testing in advanced cancers: BostonGene and Exigent Genomic INsight (BEGIN) study.

DOI: https://doi.org/10.1158/1538-7445.am2026-5421

Abstract Preview: Abstract Introduction: Growing evidence suggests that comprehensive genomic and molecular testing has the potential to enable more precise, effective, and individualized cancer care. However, outside of trials, testing is inconsistent, and adoption into practice is limited. The BostonGene and Exigent Genomic INsight Study (BEGIN; NCT06272864) is an ongoing, prospective, multi-site study evaluating...

Example 1:

Abstract Number: 6703

Title: Abstract 6703: Rg002: An mRNA-LNP-based immunotherapy targeting HPV-16/18-related malignancies

DOI: https://doi.org/10.1158/1538-7445.am2026-6703

Abstract Preview: Abstract Prophylactic vaccines against oncogenic human papillomaviruses (HPVs) are effective in preventing HPV infection but not in treating existing HPV infection and cervical intraepithelial neoplasia (CIN). Current treatments for CIN are often ablative and may lead to long-term reproductive morbidity. Thus, there is a tremendous need for therapies that can treat the millions living with persist...

Example 2:

Abstract Number: 2751

Title: Abstract 2751: Large language model-derived molecular patient similarity from real-world MTB data.

DOI: https://doi.org/10.1158/1538-7445.am2026-2751

Abstract Preview: Abstract Background: Molecular tumor boards (MTBs) frequently evaluate patients with rare molecular profiles where prospective evidence is scarce. To address this challenge, we investigated whether large language models (LLMs) can structure real-world MTB documentation into analyzable representations to identify molecularly similar patients. Methods: MTB documentation from 2,788 patients and patho...

Example 3:

Abstract Number: 7873

Title: Abstract 7873: In vivo preclinical efficacy of a novel “payload-bearing” peptide LX-101 targeting IGF-1R in Ewing sarcoma

DOI: https://doi.org/10.1158/1538-7445.am2026-7873

Abstract Preview: Abstract Ewing sarcoma (ES) is an extremely aggressive and highly metastatic bone cancer in children and young adults, ranked as the second most frequent bone tumor in pediatric patients. With a survival of ∼80% for localized and regional tumors, which can drop down to ∼40% for metastatic cases, standard treatment for ES usually includes radiotherapy, surgery, and chemotherapy based on the VDC/IE ...

Example 4:

Abstract Number: 5774

Title: Abstract 5774: Discovery of potent CDK8/CDK19 PROTAC degraders with superior anti-leukemia efficacy

DOI: https://doi.org/10.1158/1538-7445.am2026-5774

Abstract Preview: Abstract Aggressive leukemias, including acute myeloid leukemia (AML), remain highly challenging diseases due to the lack of curative therapies. AML rapidly develops resistance to both conventional and targeted treatments, underscoring the urgent need for more effective therapeutic strategies. Recently, the transcription-regulating Mediator kinases CDK8 and CDK19 have emerged as promising targets,...

Example 1:

Abstract Number: 6294

Title: Abstract 6294: Rare germline variants in key pathways contribute to hepatocellular carcinoma risk in Hispanics.

DOI: https://doi.org/10.1158/1538-7445.am2026-6294

Abstract Preview: Abstract Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related death. The primary cause of HCC is shifting from viral hepatitis infections to metabolic dysfunction-associated steatotic liver disease (MASLD). In the U.S., Hispanics have the highest incidence of HCC. Furthermore, MASLD-related HCC occurs more frequently in Hispanics ...

Example 2:

Abstract Number: 2378

Title: Abstract 2378: Cancer of unknown primary (CUP) mortality as a surrogate for imaging inequity in the United States (1999-2023)

DOI: https://doi.org/10.1158/1538-7445.am2026-2378

Abstract Preview: Abstract Background: Cancer of Unknown Primary (CUP) remains a major diagnostic and clinical challenge in oncology. Despite advances in imaging, CUP continues to account for a significant number of cancer deaths in the United States. Limited access to high-quality diagnostic imaging may delay identification of the primary tumor and contribute to persistent disparities. This study examines national...

Example 3:

Abstract Number: 7859

Title: Abstract 7859: Exploring multilevel risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD) in an electronic health record (EHR)-based cohort.

DOI: https://doi.org/10.1158/1538-7445.am2026-7859

Abstract Preview: Abstract Background: MASLD is a growing risk factor for liver cancer. Few studies have examined multilevel risk factors contributing to MASLD disparities, particularly the impact of neighborhood attributes. Elucidating multilevel risk factors can help identify groups relevant for targeted interventions to mitigate liver disease, including liver cancer. Methods: Our EHR-based cohort included adults...

Example 4:

Abstract Number: 5078

Title: Abstract 5078: Sex-specific plasma-immune architectural differences in bone marrow predicts overall survival in multiple myeloma

DOI: https://doi.org/10.1158/1538-7445.am2026-5078

Abstract Preview: Abstract Background: Multiple myeloma (MM) disproportionately affects men (57% vs. 43% women), yet the biological basis for these sex differences remains unexplored. The bone-marrow immune microenvironment, particularly plasma-immune spatial organisation, plays a critical role in disease progression and therapeutic response. Emerging evidence suggests that sex-specific immunologic differences cont...

Example 1:

Abstract Number: 6454

Title: Abstract 6454: Enhanced monocyte activation and T cell cytotoxicity underlie the benefit of neoadjuvant durvalumab plus gemcitabine-cisplatin (D+GP) in localized biliary tract cancer (BTC): Phase 2 DEBATE study

DOI: https://doi.org/10.1158/1538-7445.am2026-6454

Abstract Preview: Abstract Introduction: The prognosis of localized BTC remains poor despite surgery. The role of neoadjuvant therapy in BTC has not been well established. Methods: DEBATE is a multicenter, randomized, non-comparative phase 2 trial enrolling treatment-naïve patients (pts) with localized BTC. Pts were randomized (2:1) to receive 4 cycles of neoadjuvant D+GP or GP alone. Those undergoing surgery recei...

Example 2:

Abstract Number: 2513

Title: Abstract 2513: Exploring Ziziphus jujuba phytochemicals against oral cancer: Network-based profiling and molecular dynamics analyses

DOI: https://doi.org/10.1158/1538-7445.am2026-2513

Abstract Preview: Abstract Oral cancer remains a major global health challenge due to its complex molecular heterogeneity, limited therapeutic efficacy, and high recurrence rate. This study aimed to identify potential multi-target natural therapeutics derived from Ziziphus jujuba using an integrative computational approach. Network pharmacology was employed to map phytochemical-target interactions relevant to oral ...

Example 3:

Abstract Number: 7833

Title: Abstract 7833: A novel extraction method for enrichment of circulating cell-free DNA.

DOI: https://doi.org/10.1158/1538-7445.am2026-7833

Abstract Preview: Abstract Proximal biofluids have shown enriched sensitivity for liquid biopsy but present unique preanalytical challenges. Even in plasma, variations in collection or processing can affect cell-free DNA (cfDNA) isolation and size profiles. These differences may affect downstream sensitivity. Our lab has pioneered the use of lymphatic exudate (“lymph”) from surgical drains as a novel proximal liqui...

Example 4:

Abstract Number: 5547

Title: Abstract 5547: Enhancing antibody-dependent cellular cytotoxicityin mesothelioma through concurrent EGFR and MET targeting withamivantamab

DOI: https://doi.org/10.1158/1538-7445.am2026-5547

Abstract Preview: Abstract Background: Diffuse pleural mesothelioma (DPM) is a highly aggressive malignancy with limited treatment options and poor prognosis. Although immune checkpoint inhibitors have improved outcomes, particularly for non-epithelioid subtypes, there remains no approved targeted therapy for mesothelioma. EGFR and MET are receptor tyrosine kinases frequently overexpressed in DPM, suggesting suscep...

Example 1:

Abstract Number: 6458

Title: Abstract 6458: Harnessing tumor-informed B cell receptors for discovery and antibody-based immunotherapy in sarcoma

DOI: https://doi.org/10.1158/1538-7445.am2026-6458

Abstract Preview: Abstract Background: Soft tissue sarcomas (STS) are rare and heterogenous cancers, with limited effective treatments and poor prognosis. While some patients with STS respond to immune checkpoint blockade (ICB), the majority do not benefit. This highlights an urgent need to elucidate mechanisms of response and resistance to ICB and develop novel immunotherapeutic approaches for patients with STS. W...

Example 2:

Abstract Number: 2526

Title: Abstract 2526: Non-invasive biomarker discovery and validation for the early detection of pancreatic cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-2526

Abstract Preview: Abstract Introduction: Pancreatic malignancies are the fourth leading cause of all cancer-related deaths in the United States and this high mortality rate can be attributed to a lack of diagnostic tests for early detection. A majority of patients with pancreatic ductal adenocarcinoma (PDAC) present with advanced disease due to a lack of specific symptoms suggesting that early detection may signifi...

Example 3:

Abstract Number: 7865

Title: Abstract 7865: Survival profile of patients presented at technology-enhanced multidisciplinary cancer conferences.

DOI: https://doi.org/10.1158/1538-7445.am2026-7865

Abstract Preview: Abstract Background: Emerging research suggests that multidisciplinary cancer conferences (MCCs) positively impact survival in cancer patients. This study aimed to assess the survival outcomes in technology-enhanced thoracic, gynecology and breast tumor boards. Methods: We conducted a prospective study, pre vs post implementation of a tumor board technology platform, September 2020 to February 202...

Example 4:

Abstract Number: 5413

Title: Abstract 5413: Real-world (RW) outcomes by race in patients (pts) receiving first-line (1L) treatment (tx) for advanced/metastatic (a/m) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC).

DOI: https://doi.org/10.1158/1538-7445.am2026-5413

Abstract Preview: Abstract Prior studies show racial disparities in tx access and mortality in GC/GEJC/EAC, yet the effect of race on 1L tx outcomes is unclear. We evaluated tx patterns and outcomes by race in pts who received 1L tx for GC/GEJC/EAC in the US. This retrospective, observational study used the Flatiron Health Research Database. Adults starting 1L tx between May 1, 2021, and Nov 30, 2024 for HER2-negat...

Example 1:

Abstract Number: 6374

Title: Abstract 6374: Sodium chloride nanoparticles as urinary bladder cancer therapeutics.

DOI: https://doi.org/10.1158/1538-7445.am2026-6374

Abstract Preview: Abstract In 2025, bladder cancer ranks sixth in incidence and tenth in cancer mortality in the United States, with an estimated 84,870 new cases and 17,420 deaths. Surgical transurethral resection of bladder tumors (TURBT) is the first step in standard bladder cancer treatment, followed by adjuvant intravesical chemotherapy or immunotherapy to eliminate existing or residual tumors. Local-regional ...

Example 2:

Abstract Number: 2650

Title: Abstract 2650: Breaking immune silence: Tumor-targeted molecular therapy reprograms the tumor-immune interface in progressive neuroblastoma

DOI: https://doi.org/10.1158/1538-7445.am2026-2650

Abstract Preview: Abstract Progressive neuroblastoma (pNB) that defies intensive multimodal clinical therapy remains a challenging pediatric cancer, characterized by swift clinical deterioration, recalcitrance, and a high degree of immune evasion. Our recent investigations recognized retinal degeneration 3 (RD3) deficiency as a central molecular driver of malignant characteristics, correlating with unfavorable outc...

Example 3:

Abstract Number: 7793

Title: Abstract 7793: Bioelectromagnetic reprogramming of tumor-immune metabolism to selectively destroy NSCLC

DOI: https://doi.org/10.1158/1538-7445.am2026-7793

Abstract Preview: Abstract BACKGROUND: Dysregulated oxygen and redox-active metal metabolism create an oxidized tumor microenvironment in non-small cell lung cancer (NSCLC). Tumors accumulate reactive oxygen species (ROS) and labile iron, promoting progression yet creating a vulnerability to iron-catalyzed ROS and lipid peroxidation. This oxidized microenvironment also alters tumor-immune metabolic balance, impedin...

Example 4:

Abstract Number: 5587

Title: Abstract 5587: VTS208: A first-in-class CD3/CLDN18.2/CDH17 Tri-specific T cell engager (TCE) for the treatment of gastrointestinal (GI) cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5587

Abstract Preview: Abstract Zolbetuximab (Astellas’ anti-CLDN18.2 mAb, approved) has validated CLDN18.2 as a promising tumor-associated antigen (TAA) for gastrointestinal (GI) cancer therapy. CLDN18.2-targeting T cell engagers (TCEs), including IBI389 (phase I) and ASP2138 (phase I), demonstrate anti-tumor activity in patients with low CLDN18.2 expression, indicating that the TCE modality is effective even with mini...

Example 1:

Abstract Number: 6469

Title: Abstract 6469: Longitudinal loss of microbiome stability is associated with poor response to immune checkpoint inhibitors in lung cancer and melanoma

DOI: https://doi.org/10.1158/1538-7445.am2026-6469

Abstract Preview: Abstract While immune checkpoint inhibitors (ICI)-based regimens and chemo-immunotherapy combinations (chemo-ICI) are now first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC), the number of patients who experience a sustained response to treatment remains limited. The majority of patients will eventually develop progressive disease. Microbiome-based biomarkers offer a...

Example 2:

Abstract Number: 2538

Title: Abstract 2538: Machine learning-derived circulating ncRNA signature for early detection of breast cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-2538

Abstract Preview: Abstract Background: Breast cancer is the most commonly diagnosed cancer and a leading cause of cancer-related mortality among women in the United States. Early detection substantially improves survival, yet current imaging-based screening modalities are limited by reduced sensitivity in certain populations and high false-positive rates. Circulating non-coding RNAs (ncRNAs) represent stable and no...

Example 3:

Abstract Number: 7834

Title: Abstract 7834: DNA methylation: A highly accurate biomarker for treatment monitoring - A retrospective case study using cfDNA methylation and machine learning in breast cancer patients.

DOI: https://doi.org/10.1158/1538-7445.am2026-7834

Abstract Preview: Abstract DNA methylation plays a critical role in gene regulation and maintaining genomic stability. Abnormal DNA methylation patterns are common in breast cancer and relate to tumor growth and resistance to therapy. Liquid biopsies, especially analyzing cell-free DNA (cfDNA) in plasma, offer a minimally invasive way to monitor tumor-specific molecular changes in real time. This study evaluates th...

Example 4:

Abstract Number: 5484

Title: Abstract 5484: Designing ATP-gated proteins for tumor selective drug delivery.

DOI: https://doi.org/10.1158/1538-7445.am2026-5484

Abstract Preview: Abstract Chemotherapy remains limited by lack of specificity in many existing treatments, motivating the need for therapeutic strategies that exploit molecular features unique to the tumor microenvironment (TME). A defining hallmark of the TME is the elevated concentration of extracellular ATP (eATP), which can rise ∼1000-fold from nanomolar levels in healthy cells to ∼100 µM in tumors. eATP promo...

Example 1:

Abstract Number: 6553

Title: Abstract 6553: A comprehensive analysis of HMGB1 as a biomarker for predicting immunotherapy efficacy in small cell lung cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-6553

Abstract Preview: Abstract Background: High mobility group box 1 protein (HMGB1) is known to be associated with progression and poor prognosis of several solid tumors. However, its role in small cell lung cancer (SCLC) remains unclear. Therefore, we intend to provide the first systematically analysis of HMGB1 as a prognostic and immunotherapy predictive biomarker in SCLC. Methods: Public datasets and self-tested tr...

Example 2:

Abstract Number: 2453

Title: Abstract 2453: Valproic acid enhances immune reprogramming in locally advanced rectal cancer: Insights from the VshoRTR3 trial

DOI: https://doi.org/10.1158/1538-7445.am2026-2453

Abstract Preview: Abstract Rectal cancer, a common subtype of colorectal cancer, is rising worldwide due to lifestyle factors and aging population. Patients with locally advanced rectal cancer (LARC) are commonly treated with neoadjuvant chemoradiotherapy and surgery; however, recurrence rates remain high, ranging from 25% to 40%, depending on disease stage. Among the hallmarks of cancer, metabolic dysregulation an...

Example 3:

Abstract Number: 7751

Title: Abstract 7751: Integrative multi-omics and spatial transcriptomics reveal novel immunotherapy targets in hepatocellular carcinoma

DOI: https://doi.org/10.1158/1538-7445.am2026-7751

Abstract Preview: Abstract Background: Immunotherapy has transformed the management of hepatocellular carcinoma (HCC), yet most patients fail to achieve durable responses. The underlying single-cell-level gene-regulatory mechanisms shaping immune evasion remain poorly understood. To uncover previously unknown therapeutic vulnerabilities, we integrated single-cell multiomic profiling with spatial transcriptomics in ...

Example 4:

Abstract Number: 5941

Title: Abstract 5941: Large-scale analysis reveals distinct molecular subtypes in real-world gastric cancer data

DOI: https://doi.org/10.1158/1538-7445.am2026-5941

Abstract Preview: Abstract Introduction: Gastric cancer (GC) remains a global health concern, with limited outcome improvement despite targeted therapy. Here, a large real-world dataset of diverse disease stages and tumor sites was used to profile the molecular and clinical landscape of GC. Methods: De-identified clinico-genomic records from GC patients profiled with Tempus xT (DNA) and xR (RNA)-seq assays were ana...

Example 1:

Abstract Number: 6241

Title: Abstract 6241: High-throughput screening for cancer-relevant chemicals in hair relaxer products sold in Kenya.

DOI: https://doi.org/10.1158/1538-7445.am2026-6241

Abstract Preview: Abstract Introduction: Hair relaxer use is associated with increased risks of several hormone-related cancers, including uterine, ovarian, and breast cancer. Given the high prevalence of relaxer use among Black women and women of African ancestry, unequal exposure to toxicants in these products might contribute to observed disparities in cancer incidence and mortality. Although recent regulatory e...

Example 2:

Abstract Number: 2489

Title: Abstract 2489: Distinct HER2- breast cancer traits among subethnic Hispanics of South Florida

DOI: https://doi.org/10.1158/1538-7445.am2026-2489

Abstract Preview: Abstract Introduction: Studies with representative numbers of the predominant Caribbean and South American subethnic Hispanics of South Florida (SHFL) are limited. This study explored traits potentially linked to breast cancer susceptibility risk among SHFL, which comprise 45% of Sylvester Cancer Center's breast cancer patients. Methods: A cohort of 971 SHFL females with breast cancer records betw...

Example 3:

Abstract Number: 7703

Title: Abstract 7703: Proteomic profiling of Neem (Azadirachta indica) leaves

DOI: https://doi.org/10.1158/1538-7445.am2026-7703

Abstract Preview: Abstract Modern scientific studies have contributed largely to creating well -validated research data for the holistically rooted use of the Neem (Azadirachta Indica) tree in disease management. Neem’s astonishing historical and modern relevance reveal more evidence as to why Neem is the target of our study.Valuable studies have shown that the whole parts of the Neem tree are are markable natural ...

Example 4:

Abstract Number: 5414

Title: Abstract 5414: Clinical outcomes and treatment outcomes of stage IV large cell lung cancer based on two national database analysis.

DOI: https://doi.org/10.1158/1538-7445.am2026-5414

Abstract Preview: Abstract Background: Large cell lung cancer (LCLC) is an uncommon neuroendocrine subtype of non-small cell lung cancer with limited therapeutic options and poor prognosis. Evidence regarding survival patterns in stage IV LCLC, particularly across different treatment modalities, remains scarce. This study aimed to evaluate clinical characteristics, treatment patterns, and survival outcomes using tw...

Example 1:

Abstract Number: 6485

Title: Abstract 6485: Combination of the GCN2 activator HC-7366 with VEGFR-TKI results in greater efficacy than VEGFR-TKI alone or VEGFR-TKI/HIF-2i combinations in ccRCC

DOI: https://doi.org/10.1158/1538-7445.am2026-6485

Abstract Preview: Abstract Current standards of care for metastatic clear cell renal cell carcinoma (ccRCC) include immune checkpoint inhibitors (ICIs), VEGFR-tyrosine kinase inhibitors (VEGFR-TKIs), or the combination of both. Recently, the HIF-2α inhibitor belzutifan was approved for 2L+ metastatic ccRCC patients and its combination with ICIs or VEGFR-TKIs is being studied in clinical trials. Despite the initial ...

Example 2:

Abstract Number: 3059

Title: Abstract 3059: Targeting metabolic dependencies in MYC-driven osteosarcoma through Lp-PLA2 inhibition

DOI: https://doi.org/10.1158/1538-7445.am2026-3059

Abstract Preview: Abstract Osteosarcoma (OS) is the most prevalent pediatric bone cancer and treatment outcomes and survival rates have remained largely unchanged for decades. Patients with metastatic or relapsed/refractory disease face five-year survival rates below 30%, with no salvage therapies available after standard of care failure. Overexpression of the oncogene MYC contributes to aggressive tumor progressio...

Example 3:

Abstract Number: 7856

Title: Abstract 7856: Prevalence and association of clonal hematopoiesis with cardiovascular health in patients of the Avera sequencing and analytics protocol (ASAP) Study.

DOI: https://doi.org/10.1158/1538-7445.am2026-7856

Abstract Preview: Abstract Introduction: Clonal Hematopoiesis (CH) refers to age-associated somatic mutations in hematopoietic stem cells. CH may be incidentally discovered in oncology patients via next-generation sequencing. Cancer therapies such as cytotoxic chemotherapy and radiation can accelerate the development or expansion of CH, particularly in genes associated with therapy-related myeloid neoplasms. Certai...

Example 4:

Abstract Number: 5956

Title: Abstract 5956: Effect of the evolutionary selected Andean Aymara NFKB1 polymorphisms on inflammatory and HIF-dependent gene expression in endometrial and ovarian cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5956

Abstract Preview: Abstract JS,SS-corresponding authors; SJK, AP-equal contributionGynecological cancers cause ∼132/1 million deaths in women /year worldwide (PMID: 39148469). Endometrial cancer (EC) is the most common gynecological cancer, while ovarian cancer (OC) is the most lethal, with a 5-year US mortality ∼51% overall and less than 30% in advanced stage of disease. NF-κB signaling contributes to progression, ...

Example 1:

Abstract Number: 6229

Title: Abstract 6229: Neighborhood analyses in nerve fiber-associated tumor regions in hereditary diffuse gastric cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-6229

Abstract Preview: Abstract Background: In carcinomas, perineural invasion and tumor-nerve niches are increasingly recognized as associated with cancer progression. In Hereditary Diffuse Gastric Cancer (HDGC), the molecular programs behind these interactions are not fully understood. In this study, we aim to depict multicellular neighborhoods and spatial transcriptomics programs associated with tumor-nerve interacti...

Example 2:

Abstract Number: 2433

Title: Abstract 2433: BAP1 loss confers ferroptosis resistance to cholangiocarcinoma via TLCD1-mediated membrane phospholipid remodeling

DOI: https://doi.org/10.1158/1538-7445.am2026-2433

Abstract Preview: Abstract INTRODUCTION: Cholangiocarcinoma (CCA) is a deadly cancer of the hepatic bile duct epithelial cells. Loss-of-function mutations of epigenetic regulator ubiquitin C-terminal hydrolase deubiquitinase BRCA1-associated protein 1 (BAP1) occur in 26-32% of human CCA and are associated with worse prognosis and resistance to cytotoxic therapy. The goal of this study is to identify how BAP1 loss p...

Example 3:

Abstract Number: 7700

Title: Abstract 7700: Secretomic profiling of triple-negative breast cancer media using Mag-Net™ HP

DOI: https://doi.org/10.1158/1538-7445.am2026-7700

Abstract Preview: Abstract Introduction: Secretomics provides a real-time view of tumor biology by profiling proteins that cancer cells release into their microenvironment and circulation. In breast and other cancers, secreted factors can serve as predictive and prognostic markers of disease state and treatment response. However, conventional mass-spectrometry workflows often miss low-abundance cytokines, growth fa...

Example 4:

Abstract Number: 5666

Title: Abstract 5666: Tambiciclib (SLS009), a CDK9 inhibitor, promotes apoptosis and suppresses MCL-1 levels in AML cell lines.

DOI: https://doi.org/10.1158/1538-7445.am2026-5666

Abstract Preview: Abstract Background: Tambiciclib (SLS009) is a potent, selective CDK9 inhibitor that has shown promising results in Phase I clinical trials in hematological malignancies (NCT04588922). CDK9 is a critical regulator of transcription elongation through RNA polymerase II. Its inhibition results in downregulation of protein synthesis, thus decreasing the expression of short half-life molecules, such as...

Example 1:

Abstract Number: 6473

Title: Abstract 6473: Clonal consolidation and transcriptional re-programming define non-small cell lung cancers resistant to immune checkpoint inhibitors

DOI: https://doi.org/10.1158/1538-7445.am2026-6473

Abstract Preview: Abstract Analysis of pre-treatment non-small cell lung cancers (NSCLCs) has helped identify predictors of response to immune checkpoint inhibitors (ICI), including low PD-L1 expression, targetable drivers alterations (EGFR, ALK), and STK11/KEAP1 mutations. To-date, however, few samples at treatment resistance have been studied, and consequently less is known about the mechanisms contributing to IC...

Example 2:

Abstract Number: 2399

Title: Abstract 2399: Discovery of ZL-6201, a novel LRRC15-targeting antibody drug conjugate (ADC) for the treatment of sarcomas and epithelial solid tumors.

DOI: https://doi.org/10.1158/1538-7445.am2026-2399

Abstract Preview: Abstract Leucine-rich repeat-containing protein 15 (LRRC15) is a transmembrane protein involved in cell-cell and cell-extracellular matrix interactions. It is overexpressed in tumors of mesenchymal origin which include sarcomas, glioblastoma and melanoma, where its expression has been implicated in promoting metastasis. Additionally, LRRC15 is upregulated in cancer-associated fibroblasts (CAFs) th...

Example 3:

Abstract Number: 7871

Title: Abstract 7871: Onvansertib-mediated PLK1 inhibition reduces cell viability in neuroblastoma cells

DOI: https://doi.org/10.1158/1538-7445.am2026-7871

Abstract Preview: Abstract Background: Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for a significant proportion of pediatric cancer-related mortality. Despite advances in multimodal therapy including intensive chemotherapy, radiotherapy, stem cell transplantation, patients with high-risk disease continue to experience poor long-term survival. Consequently, there is an urgent ...

Example 4:

Abstract Number: 5670

Title: Abstract 5670: Oxidative stress-mediated non-apoptotic, non-autophagic cell death: A mechanistically distinct strategy to overcome resistance in colorectal cancer cells.

DOI: https://doi.org/10.1158/1538-7445.am2026-5670

Abstract Preview: Abstract Cancer remains a leading cause of mortality worldwide, with therapeutic failure often driven by apoptosis resistance a major hurdle that limits the efficacy of conventional anticancer therapies. Targeting alternative, caspase-independent cell death pathways has emerged as a promising strategy to overcome this resistance. In this study, we evaluated the effects of two mechanistically disti...

Example 1:

Abstract Number: 6577

Title: Abstract 6577: A potential role of NRF-2, MDR-1, and TET-2 in inflammatory bowel disease and colorectal carcinoma: An in vitro study

DOI: https://doi.org/10.1158/1538-7445.am2026-6577

Abstract Preview: Abstract Study purpose: Inflammatory Bowel Disease (IBD) is partly attributed to cytokine storm and infiltrating immune cells. As part of the cell defensive mechanisms, a transcription factor called nuclear factor erythroid 2-related factor 2 (NRF-2) activates genes encoding antioxidant enzymes. Additionally, NRF-2 has recently emerged as an important contributor to chemo-resistance in colon neopl...

Example 2:

Abstract Number: 2557

Title: Abstract 2557: Glucocorticoids inhibit the GARP/TGF-βaxis initiating immune-dependent melanoma control

DOI: https://doi.org/10.1158/1538-7445.am2026-2557

Abstract Preview: Abstract Melanoma is the form of skin cancer responsible for most patient deaths. Treatment with immune checkpoint blockade (ICB) has led to a significant improvement in outcomes. However, half of melanoma patients do not derive long-term benefit, and improved understanding of this is required to identify novel mechanisms of resistance and treatment. We screened a range of topical treatments, used...

Example 3:

Abstract Number: 7828

Title: Abstract 7828: Development of a comprehensive tumor-informed ctDNA workflow for ultrasensitive molecular residual disease detection using diverse tumor profiling inputs.

DOI: https://doi.org/10.1158/1538-7445.am2026-7828

Abstract Preview: Abstract Background: Circulating tumor DNA (ctDNA) analysis represents a transformative approach to molecular residual disease (MRD) surveillance, enabling non-invasive disease monitoring and treatment response assessment. While tumor-agnostic methodologies offer broad applicability, tumor-informed strategies leveraging patient-specific genomic alterations can provide enhanced sensitivity for dete...

Example 4:

Abstract Number: 5644

Title: Abstract 5644: DA-3501 (AT-211): Evaluation of immune-mediated antitumor activity and combination immunotherapy potential of a site-specific CLDN18.2-targeting antibody-drug conjugate (ADC).

DOI: https://doi.org/10.1158/1538-7445.am2026-5644

Abstract Preview: Abstract Background: Claudin 18.2 (CLDN18.2) is a clinically validated therapeutic target in gastric and pancreatic cancers. However, acquired resistance to CLDN18.2-directed antibodies such as zolbetuximab and trastuzumab highlights the need for next-generation therapeutics with distinct mechanisms of action. DA-3501 (AT-211) is a CLDN18.2-targeting antibody-drug conjugate (ADC) developed using t...

Example 1:

Abstract Number: 6394

Title: Abstract 6394: Ferroptosis amplified by a tumor-targeted artesunate nano-derivative for effective colon cancer treatment.

DOI: https://doi.org/10.1158/1538-7445.am2026-6394

Abstract Preview: Abstract Background: Artesunate (ART), a proven antimalarial drug, is promising but has limited antitumor activity because of its poor stability, low potency, and lack of tumor selectivity. While its effect is linked to ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, clinical translation in oncology requires enhanced drug delivery and targeting. We hypothesized that...

Example 2:

Abstract Number: 2709

Title: Abstract 2709: PRECISE: A prognostic thyroid follicular cell-derived gene signature for papillary thyroid carcinoma.

DOI: https://doi.org/10.1158/1538-7445.am2026-2709

Abstract Preview: Abstract Purpose: Papillary thyroid carcinoma (PTC) exhibits heterogeneous behavior. There is a need for effective biomarkers and improved risk stratification methods in PTC. Gene signatures derived from bulk RNA sequencing capture composite transcriptional profiles that are confounded by tumor microenvironment cells. We developed a thyroid follicular cell-derived gene signature, Prognostic RNA Ex...

Example 3:

Abstract Number: 7793

Title: Abstract 7793: Bioelectromagnetic reprogramming of tumor-immune metabolism to selectively destroy NSCLC

DOI: https://doi.org/10.1158/1538-7445.am2026-7793

Abstract Preview: Abstract BACKGROUND: Dysregulated oxygen and redox-active metal metabolism create an oxidized tumor microenvironment in non-small cell lung cancer (NSCLC). Tumors accumulate reactive oxygen species (ROS) and labile iron, promoting progression yet creating a vulnerability to iron-catalyzed ROS and lipid peroxidation. This oxidized microenvironment also alters tumor-immune metabolic balance, impedin...

Example 4:

Abstract Number: 5501

Title: Abstract 5501: A quantum-enabled atlas-scale resource to study metabolic landscapes and heterogeneity in cancer TME.

DOI: https://doi.org/10.1158/1538-7445.am2026-5501

Abstract Preview: Abstract Metabolic networks are profoundly rewired in cancer, supporting uncontrolled proliferation, immune evasion, and therapy resistance. Although large atlas-level single-cell RNA-seq (scRNA-seq) datasets of cancer tumor microenvironments (TMEs) and normal human tissues are now available, there remains no systematic, genome-scale characterization of metabolic landscapes, shifts, heterogeneity,...

Example 1:

Abstract Number: 6384

Title: Abstract 6384: Nanoparticle mediated disruption of tumor-nerve crosstalk enhances pancreatic cancer treatment and pain mitigation.

DOI: https://doi.org/10.1158/1538-7445.am2026-6384

Abstract Preview: Abstract Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal prognosis. Dense fibrous tumor stroma creates a drug delivery barrier, cultivates aggressive tumor biology and immunosuppression in PDAC. A well-recognized hallmark of PDAC is nerve infiltration into tumors and cancer cells invading neurons, which correlate with local invasion and poor su...

Example 2:

Abstract Number: 2602

Title: Abstract 2602: Impact of targeted therapies in cancers classified as TMB-high by liquid biopsy: Insights from the Gustave Roussy molecular tumor board

DOI: https://doi.org/10.1158/1538-7445.am2026-2602

Abstract Preview: Abstract Background: Tumor mutational burden (TMB) has emerged as a biomarker for immunotherapy response, but its predictive value for targeted therapies remains uncertain. In genomically unstable tumors, high TMB may reflect passenger rather than driver events, potentially limiting the efficacy of targeted agents. Methods: We retrospectively analyzed adult patients with advanced solid tumors who ...

Example 3:

Abstract Number: 7853

Title: Abstract 7853: A seven-gene mutation signature predicts immunotherapy benefit in bladder cancer.

DOI: https://doi.org/10.1158/1538-7445.am2026-7853

Abstract Preview: Abstract Introduction: Immunotherapy plays an important role in advanced bladder cancer. However, no mutation-based biomarker has been established to reliably predict immunotherapy benefit in bladder cancer. This study aimed to identify the gene mutation signature predicting immunotherapy efficacy. Method: We retrieved genetic and clinical data of patients with bladder cancer and immunotherapy tre...

Example 4:

Abstract Number: 5725

Title: Abstract 5725: Targeting Rac1 as a therapeutic vulnerability in T-cell lymphomas

DOI: https://doi.org/10.1158/1538-7445.am2026-5725

Abstract Preview: Abstract T-cell lymphomas (TCL) are aggressive and heterogeneous neoplasms with limited therapeutic options and poor prognosis, underscoring the need for novel molecular targets. Here, we investigated Rac1, a Rho GTPase that regulates cytoskeletal dynamics, migration, and survival pathways, as a potential therapeutic vulnerability in TCL. Its central role in these tumor-promoting processes suggest...

Example 1:

Abstract Number: 6194

Title: Abstract 6194: Spatial architecture of immunochemotherapy response in pleural mesothelioma

DOI: https://doi.org/10.1158/1538-7445.am2026-6194

Abstract Preview: Abstract Introduction: Pleural mesothelioma (PM) is a rare and aggressive malignancy originating from the mesothelial cells of the pleural lining, with a well-established etiological association with asbestos exposure. Although immunochemotherapy is being applied as a first-line treatment, most patients fail to respond to the therapy. Previous single-cell RNA sequencing studies on PM have revealed...

Example 2:

Abstract Number: 2506

Title: Abstract 2506: Genomic-driven targeted therapy evaluation using patient-derived organoids and xenografts in gastric cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-2506

Abstract Preview: Abstract Background: Gastric cancer (GC) exhibits significant molecular heterogeneity that hampers the effectiveness of standard therapies. Reliable preclinical models that accurately reflect patient-specific biology are urgently needed to inform precision treatments. Patient-derived organoids (PDOs) and xenografts (PDXs) provide complementary platforms for assessing targeted therapies. Methods: W...

Example 3:

Abstract Number: 7827

Title: Abstract 7827: Analytical evaluation of tumor-naive ctDNA molecular response detection through baseline informed comprehensive genomic profiling with matched white blood cell analyses.

DOI: https://doi.org/10.1158/1538-7445.am2026-7827

Abstract Preview: Abstract Liquid biopsies can provide an improvement over existing diagnostic modalities to detect, characterize and monitor cancer across the care continuum. Circulating tumor DNA (ctDNA) dynamics have been shown to identify cancer progression earlier than can be achieved with imaging-based assessments, however, can be limited due to low tumor burden together with the biological background associa...

Example 4:

Abstract Number: 5755

Title: Abstract 5755: MTORC1/2 inhibition enhances STX-478, a PIK3CA H1047R mutant inhibitor, in PIK3CA H1047R mutant colorectal cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5755

Abstract Preview: Abstract Background: STX-478, a PIK3CA mutant selective inhibitor, that we have previously shown to have promise in treating PIK3CAH1047R mutant colorectal cancer (CRC) models. A high throughput drug screen was performed and identified AZD2014, an MTORC1/2 inhibitor, to have enhanced response with STX-478. Here, we examine the combination of PI3K inhibition with MTORC1/2 inhibition in PIK3CAH1047R...

Example 1:

Abstract Number: 6492

Title: Abstract 6492: Targeting phospholipase D1 overcomes platinum resistance and enhances cisplatin efficacy in ovarian cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-6492

Abstract Preview: Abstract Background: Platinum-based chemotherapy is the standard treatment for high-grade serous ovarian cancer (HGSOC), yet the development of platinum resistance remains a major barrier to effective therapy. Phospholipase D1 (PLD1) has been implicated in tumor progression and stress response pathways, but its potential as a therapeutic target in platinum-resistant ovarian cancer (OC) has not bee...

Example 2:

Abstract Number: 2553

Title: Abstract 2553: Multi-omics liquid biopsy approach for sensitive detection of lung cancer via cfDNA and extracellular vesicles-RNA

DOI: https://doi.org/10.1158/1538-7445.am2026-2553

Abstract Preview: Abstract Background: Early detection of lung cancer remains challenging due to tumor heterogeneity and the limitations of single-analyte assays. Circulating cell-free DNA (cfDNA) captures genomic alterations, including mutations, copy number variations, and methylation patterns, but does not reflect gene activity. Circulating extracellular vesicles (EVs) carry varieties of small non-coding RNAs re...

Example 3:

Abstract Number: 7855

Title: Abstract 7855: Transcriptomic profiling of Ki67 expression in melanoma patient specimens reveals distinct immune signatures.

DOI: https://doi.org/10.1158/1538-7445.am2026-7855

Abstract Preview: Abstract Background: The Ki67 gene (MKI67) is clinically relevant as a marker of high cellular activity in melanoma among other cancer subtypes. We hypothesized that transcriptomic profiling of human melanoma tissue as stratified by MIK67-high and MKI67-low expression may correlate with immune signatures of biologic activity and with clinical outcomes. Methods: Analyzed tumor tissue included subcu...

Example 4:

Abstract Number: 5571

Title: Abstract 5571: Dynamic transcriptional remodeling and functional adaptation drive malignant progression in lymphoma

DOI: https://doi.org/10.1158/1538-7445.am2026-5571

Abstract Preview: Abstract Background: Lymphoma progression is shaped by dynamic interactions between malignant B cells and the tumor microenvironment, generating marked transcriptional and functional heterogeneity. To define mechanisms driving this adaptive evolution, we developed a transplantable oncogene-driven lymphoma model enabling controlled tracking of clonal evolution, transcriptional remodeling, and funct...

Example 1:

Abstract Number: 6331

Title: Abstract 6331: A translational framework for high-plex spatial profiling and complexity reduction toward diagnostic assay development in colorectal polyps

DOI: https://doi.org/10.1158/1538-7445.am2026-6331

Abstract Preview: Abstract Background: Accurate risk stratification of colorectal polyps is essential for reducing unnecessary surveillance while ensuring that high-risk patients receive timely intervention. Pathology workflows rely on morphology from H&E slides, while emerging immune-profiling techniques such as multiplex immunofluorescence (mIF) offer deeper biological resolution but are often too complex and...

Example 2:

Abstract Number: 2327

Title: Abstract 2327: Thymic radiation and oncologic outcomes

DOI: https://doi.org/10.1158/1538-7445.am2026-2327

Abstract Preview: Abstract Background The thymus plays a crucial role in early life, serving as the primary source of T-cell development, a vital component of adaptive immunity. Despite its central role in immune biology, the thymus is not currently considered an organ-at-risk in Radiotherapy (RT). RT, a cornerstone of treatment for locally advanced non-small cell lung cancer (NSCLC), has effects extending beyond l...

Example 3:

Abstract Number: 7697

Title: Abstract 7697: Machine learning-based plasma proteomic signatures for diagnosis and prognosis of cholangiocarcinoma

DOI: https://doi.org/10.1158/1538-7445.am2026-7697

Abstract Preview: Abstract Background: Cholangiocarcinoma (CCA) lacks reliable non-invasive biomarkers for early diagnosis and individualized prognostic assessment. Circulating proteomic profiling offers an opportunity to develop clinically actionable molecular signatures.Methods: A total of 320 plasma samples were collected across two centers, including patients with CCA, benign biliary disease, and healthy contro...

Example 4:

Abstract Number: 5357

Title: Abstract 5357: Molecular tumor registries - A learning system for real world data (RWD).

DOI: https://doi.org/10.1158/1538-7445.am2026-5357

Abstract Preview: Abstract Background: Genomic data is a key component for drug discovery and precision medicine, an innovative approach for tailoring treatment and prevention that is useful for clinicians and researchers. Patient care now often involves comprehensive genomic profiling through certified clinical lab vendors. The clinical interpretation of molecular alterations is at the heart of providing the value...

Example 1:

Abstract Number: 6427

Title: Abstract 6427: BRETTSA: A BRET-based assay for ultra-sensitive measurement of target engagement through protein denaturation in live cells

DOI: https://doi.org/10.1158/1538-7445.am2026-6427

Abstract Preview: Abstract Understanding ligand-target interactions within the native cellular environment is a persistent challenge in early drug discovery. Conventional thermal shift assays (TSAs) enable evaluation of target engagement in cells with minimal prior knowledge of the target, but their reliance on protein aggregation limits both sensitivity and scalability for high-throughput screening (HTS). We intro...

Example 2:

Abstract Number: 2540

Title: Abstract 2540: A combined bioinformatics, deep learning analysis, and immunohistochemistry approach to define the biomarker potential of advanced glycosylated end products (AGER) complex proteins in colon cancer progression

DOI: https://doi.org/10.1158/1538-7445.am2026-2540

Abstract Preview: Abstract Background: Despite recent advances in colorectal cancer (CRC) diagnosis and population screening programs, the identification of patients with preneoplastic lesions or with early CRC stages remains challenging and is essential for reducing CRC incidence and increasing patients’ survival. Methods: Our study comprehensively investigated the clinical significance and relationship among AGER...

Example 3:

Abstract Number: 7705

Title: Abstract 7705: Simultaneous quantitation and discovery of cancer-related proteins in plasma using a fast, high-resolution accurate mass spectrometry-based assay provides insight into precision oncology and drug discovery

DOI: https://doi.org/10.1158/1538-7445.am2026-7705

Abstract Preview: Abstract The inherent heterogeneity of cancer has spurred significant technological advancements to enhance the detailed study required to characterize this complex disease, predominantly defined by uncontrolled changes. Efforts to address and treat this multi-faceted variability are executed as investigation of plasma - a readily accessible biological fluid rich in information regarding physiolog...

Example 4:

Abstract Number: 5506

Title: Abstract 5506: An ensemble machine learning approach to ALT detection revals therapeutic vulnerabilities in pediatric cancers lacking actionable drug targets.

DOI: https://doi.org/10.1158/1538-7445.am2026-5506

Abstract Preview: Abstract Alternative lengthening of telomeres (ALT) maintains telomeres in 15-20% of cancers through a recombination-based mechanism associated with poor outcomes. ALT is frequently driven by ATRX/DAXX loss-of-function mutations and is enriched in pediatric malignancies including osteosarcoma, neuroblastoma, and soft tissue sarcomas—cancers with limited therapeutic options. Current ALT detection m...

Example 1:

Abstract Number: 6767

Title: Abstract 6767: Defining a molecular signature for KEAP1-NRF2 mediated resistance to KRAS inhibition in KRAS-mutant pancreatic and lung cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-6767

Abstract Preview: Abstract Mutational activation of KRAS is critical for driving the tumorigenic growth of pancreatic ductal adenocarcinoma (PDAC) and lung adenocarcinoma (LUAD). Recent approval of inhibitors of one KRAS mutation (G12C) supports the therapeutic value of targeting mutant KRAS in PDAC and LUAD. However, clinical efficacy is hindered by both primary and treatment-associated acquired resistance. With r...

Example 2:

Abstract Number: 2229

Title: Abstract 2229: RIPK2 and CDK2 form a targetable positive feedback loop in prostate cancer cells.

DOI: https://doi.org/10.1158/1538-7445.am2026-2229

Abstract Preview: Abstract Background: Prostate cancer (PC) metastasis is the leading cause of PC-related mortality, yet effective therapies targeting this lethal process remain lacking. We previously identified RIPK2 as a promising drug target in PC metastasis, functioning in part through a noncanonical RIPK2/MKK7/c-Myc phosphorylation pathway (Nat. Commun., 2022). However, additional downstream effectors and upst...

Example 3:

Abstract Number: 7784

Title: Abstract 7784: Targeting PRMT7 elicits anti-AML immunity by promoting MHC-I expression

DOI: https://doi.org/10.1158/1538-7445.am2026-7784

Abstract Preview: Abstract Protein arginine methylation regulates several cellular functions, including RNA splicing, translation and DNA damage repair. Protein arginine N-methyltransferase (PRMT) dysregulation is often seen in malignant hematopoiesis. PRMT7, the only type III PRMT, catalyzes monomethyl arginine (MMA) modification, but its role in leukemogenesis is elusive. Re-analysis of a previous genome-wide CRI...

Example 4:

Abstract Number: 5895

Title: Abstract 5895: The role of noncoding transcripts in glucose-dependent gene regulation in estrogen receptor-positive breast cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5895

Abstract Preview: Abstract Around seventy percent of breast cancers are of the estrogen receptor-positive (ER+) molecular subtype. Conventional treatments include endocrine therapy that antagonizes ER signaling with tamoxifen or aromatase inhibitors. However, over 50% of patients later develop resistance and relapse. Understanding the underlying molecular mechanisms by which ER drives breast cancer will provide new...

Example 1:

Abstract Number: 6168

Title: Abstract 6168: Investigating the mechanism of oncogenesis of BCOR-CCNB3 fusion positive sarcomas

DOI: https://doi.org/10.1158/1538-7445.am2026-6168

Abstract Preview: Abstract BCOR-CCNB3 sarcomas (BCS) are a subtype of small cell sarcomas that represent a recently recognized group of solid tumors identified by rearrangements of BCOR. Gene expression profiles of patient samples demonstrate a very similar profile to other BCOR rearranged solid tumors, such as BCOR-MAML3 fusion sarcomas, and CCSK with BCOR ITD. BCOR is a corepressor of the transcription factor BCL...

Example 2:

Abstract Number: 2312

Title: Abstract 2312: ASH-MARCC: Assessment of smoking history via methylation and reference-based cell composition in human tissue samples

DOI: https://doi.org/10.1158/1538-7445.am2026-2312

Abstract Preview: Abstract Introduction: Cigarette smoking (CS) is associated with adverse health effects, including an increased risk of cancer development. Epigenome-wide association studies (EWAS) show that CS significantly alters DNA methylation (DNAm). While several DNAm-based predictors of smoking history have been trained using blood samples, their accuracy in tissue types remains limited. We aimed to develo...

Example 3:

Abstract Number: 7832

Title: Abstract 7832: Plasma epigenomic profiling captures B-cell lymphoma biology.

DOI: https://doi.org/10.1158/1538-7445.am2026-7832

Abstract Preview: Abstract Background: B-cell lymphomas (BCLs), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), display widespread epigenetic dysregulation. The histone methyltransferase EZH2 catalyzes the repressive mark H3K27me3 and is an important epigenetic regulator for B-cell development. Although previous work has examined H3K27me3 in BCL tumour samples, the landscape of H3K27me...

Example 4:

Abstract Number: 5482

Title: Abstract 5482: MethylFM: A DNA methylation foundation model for modeling epigenomic regulatory dynamics.

DOI: https://doi.org/10.1158/1538-7445.am2026-5482

Abstract Preview: Abstract DNA methylation regulates gene expression, differentiation, and disease, making it a key target for computational modeling in precision medicine. To integrate high-resolution whole-genome bisulfite sequencing (WGBS) data into a unified analytical framework, we developed MethylFM, a transformer-based foundation model that captures context-aware methylation patterns and supports multiple do...

Example 1:

Abstract Number: 6606

Title: Abstract 6606: Overcoming reduced efficacy of fractionated radiotherapy in obese mice.

DOI: https://doi.org/10.1158/1538-7445.am2026-6606

Abstract Preview: Abstract Purpose/Objective(s): Obesity is a medical condition of excess adiposity characterized by chronic inflammation and connected to comorbidities including metabolic disorders and cancer. Identifying how to best treat the growing number of obese cancer patients is paramount particularly as clinical data has implicated poorer outcomes following radiotherapy (RT) in obese patients. We observed ...

Example 2:

Abstract Number: 2570

Title: Abstract 2570: Reprogramming T-cell networks to overcome immune evasion in ovarian cancer relapse

DOI: https://doi.org/10.1158/1538-7445.am2026-2570

Abstract Preview: Abstract Ovarian cancer (OC) remains a major clinical challenge due to its high recurrence rates and resistance to standard therapies. High-grade serous ovarian cancer (HGSOC), the most common and aggressive OC subtype, often presents with tumor-infiltrating lymphocytes (TILs), yet immune checkpoint blockade (ICB) therapies have shown limited efficacy. Our studies aim to dissect the spatiotemporal...

Example 3:

Abstract Number: 7862

Title: Abstract 7862: Population analysis and immunologic landscape of melanoma in people living with HIV.

DOI: https://doi.org/10.1158/1538-7445.am2026-7862

Abstract Preview: Abstract Purpose: To dissect the clinical and immunological features of people living with HIV (PLWH) diagnosed with melanoma, who have consistently shown worse outcomes than HIV-negative individuals (PLw/oH) with the same cancer. Experimental Design: We analyzed electronic health records from 1,087 PLWH and 394,437 PLw/oH with melanoma. Demographic and clinical characteristics were compared. Spat...

Example 4:

Abstract Number: 5687

Title: Abstract 5687: Targeting KIFC1 induces anaphase catastrophe in small cell lung cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5687

Abstract Preview: Abstract Cancer cells often possess more than two centrosomes, which is one of the hallmarks of cancer. By clustering these supernumerary centrosomes during mitosis, cancer cells can achieve bipolar division. We previously reported that in non-small cell lung cancer, CDK2 inhibition suppresses centrosome clustering, leading to multipolar cell division and apoptotic cell death—a phenomenon termed a...

Example 1:

Abstract Number: 6454

Title: Abstract 6454: Enhanced monocyte activation and T cell cytotoxicity underlie the benefit of neoadjuvant durvalumab plus gemcitabine-cisplatin (D+GP) in localized biliary tract cancer (BTC): Phase 2 DEBATE study

DOI: https://doi.org/10.1158/1538-7445.am2026-6454

Abstract Preview: Abstract Introduction: The prognosis of localized BTC remains poor despite surgery. The role of neoadjuvant therapy in BTC has not been well established. Methods: DEBATE is a multicenter, randomized, non-comparative phase 2 trial enrolling treatment-naïve patients (pts) with localized BTC. Pts were randomized (2:1) to receive 4 cycles of neoadjuvant D+GP or GP alone. Those undergoing surgery recei...

Example 2:

Abstract Number: 2521

Title: Abstract 2521: Illuminating the kinase starmap in NSCLC via tyrosine phosphoproteomics

DOI: https://doi.org/10.1158/1538-7445.am2026-2521

Abstract Preview: Abstract In lung cancer treatment, understanding kinase activity, particularly tyrosine phosphorylation, is crucial but incomplete. We studied tyrosine phosphoproteomics in 74 patients with non-small-cell lung cancer (NSCLC) using SH2-Superbinder and data-independent acquisition mass spectrometry. We constructed a tyrosine phosphorylation starmap, This starmap is presented as an interactive force-...

Example 3:

Abstract Number: 7833

Title: Abstract 7833: A novel extraction method for enrichment of circulating cell-free DNA.

DOI: https://doi.org/10.1158/1538-7445.am2026-7833

Abstract Preview: Abstract Proximal biofluids have shown enriched sensitivity for liquid biopsy but present unique preanalytical challenges. Even in plasma, variations in collection or processing can affect cell-free DNA (cfDNA) isolation and size profiles. These differences may affect downstream sensitivity. Our lab has pioneered the use of lymphatic exudate (“lymph”) from surgical drains as a novel proximal liqui...

Example 4:

Abstract Number: 5561

Title: Abstract 5561: LILRB1 antibody targeting the LILRB1/HLA-G axis: Preclinical efficacy, pharmacokinetics, and safety supporting first-in-human trials

DOI: https://doi.org/10.1158/1538-7445.am2026-5561

Abstract Preview: Abstract Background: LILRB1 is an inhibitory receptor expressed on T cells, B cells, NK cells, and monocytes. It binds to HLA class I molecules, with the highest affinity for HLA-G. This interaction delivers inhibitory signals that allow tumor cells to evade immune surveillance, impairing NK cell, T cell, and macrophage function. Disrupting the LILRB1/HLA-G axis is a promising strategy for restori...

Example 1:

Abstract Number: 6175

Title: Abstract 6175: Development of a human neuroblastoma organoid model

DOI: https://doi.org/10.1158/1538-7445.am2026-6175

Abstract Preview: Abstract Neuroblastoma (NB) is the most prevalent solid malignancy in infants, with approximately 20% of cases classified as high-risk due to amplification of the MYCN oncogene - a marker associated with aggressive tumor behavior and poor prognosis. Despite therapeutic advances, relapsed high-risk NB accounts for nearly 15% of pediatric cancer-related mortality. Studies using non-human models may ...

Example 2:

Abstract Number: 2654

Title: Abstract 2654: DB-1421, an optimized EGFR/MUC1 bispecific ADC, exhibits improved tumor selectivity, promising efficacy and safety in preclinical studies

DOI: https://doi.org/10.1158/1538-7445.am2026-2654

Abstract Preview: Abstract Introduction: Epidermal growth factor receptor (EGFR) is a well-known and validated target for anti-tumor therapies. However, anti-EGFR therapy in clinical showed obvious safety concerns because of broad EGFR expression in normal tissue, and such adverse effects limit the efficacy of these products. Mucin 1 (MUC1) is highly co-expressed with EGFR in multiple tumor types including esophage...

Example 3:

Abstract Number: 7780

Title: Abstract 7780: The first-in-class covalent peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates immune phenotypes in mesothelioma

DOI: https://doi.org/10.1158/1538-7445.am2026-7780

Abstract Preview: Abstract RSO-021 is the clinical formulation of the first-in-class covalent peroxiredoxin 3 (PRX3) inhibitor thiostrepton (TS). TS covalently inactivates PRX3 active site cysteines leading to increased oxidative stress and apoptotic tumor cell death. RSO-021 was safe and showed early anti-tumor activity in a phase 1 trial in patients with malignant pleural effusion (MPE) arising from mesothelioma ...

Example 4:

Abstract Number: 5534

Title: Abstract 5534: INCA036873, a first-in-class CD70×CD3 T cell-redirecting bispecific antibody, for the treatment of CD70-positive malignancies

DOI: https://doi.org/10.1158/1538-7445.am2026-5534

Abstract Preview: Abstract CD70 is a member of the tumor necrosis factor ligand superfamily, with CD27 being its sole receptor. Under normal physiological conditions, CD70-CD27 signaling promotes T-cell activation, survival, and differentiation. In normal tissues, CD70 expression is restricted to activated T, B, and dendritic cells. Aberrant CD70 expression is observed in various malignancies, including renal cell ...

Example 1:

Abstract Number: 6737

Title: Abstract 6737: Selective degradation of pathologic multimers via a novel TRIM21-engaging molecular glue and PROTAC platform.

DOI: https://doi.org/10.1158/1538-7445.am2026-6737

Abstract Preview: Abstract Background: Targeted protein degradation (TPD) holds great promise for cancer therapy, but its application is often constrained by the limited repertoire of E3 ligases and the challenge of selectively eliminating pathologic protein assemblies, such as those driving oncogenesis, while sparing monomeric forms. The E3 ligase TRIM21 is a compelling yet underexplored effector, as its activatio...

Example 2:

Abstract Number: 2433

Title: Abstract 2433: BAP1 loss confers ferroptosis resistance to cholangiocarcinoma via TLCD1-mediated membrane phospholipid remodeling

DOI: https://doi.org/10.1158/1538-7445.am2026-2433

Abstract Preview: Abstract INTRODUCTION: Cholangiocarcinoma (CCA) is a deadly cancer of the hepatic bile duct epithelial cells. Loss-of-function mutations of epigenetic regulator ubiquitin C-terminal hydrolase deubiquitinase BRCA1-associated protein 1 (BAP1) occur in 26-32% of human CCA and are associated with worse prognosis and resistance to cytotoxic therapy. The goal of this study is to identify how BAP1 loss p...

Example 3:

Abstract Number: 7785

Title: Abstract 7785: Spatial profiling reveals epigenetic and immunotherapy-driven remodeling of the tumor and lymph node microenvironment in HPV-associated HNSCC

DOI: https://doi.org/10.1158/1538-7445.am2026-7785

Abstract Preview: Abstract Human papillomavirus (HPV) leads to most oropharynx cancers in the United States, with increasing incidence, significant morbidity from therapy and mortality from metastatic recurrence. HPV+ tumors exhibit a higher cure rate with surgery or chemoradiation but display lower sensitivity to immune checkpoint inhibitors (ICI). Tumor-draining lymph nodes (LNs), crucial for antigen presentation...

Example 4:

Abstract Number: 5907

Title: Abstract 5907: Splicing of 3’UTR contributes to colon cancer progression

DOI: https://doi.org/10.1158/1538-7445.am2026-5907

Abstract Preview: Abstract The 3′ untranslated regions (3′UTRs) of messenger RNAs (mRNAs) play crucial roles in regulating gene expression. These regions have been found to be involved in important processes, including mRNA stability, localization, and translation. It is shown that 3’UTR splicing is widespread in many cancers and dysregulated 3′UTR splicing leads to cytoplasmic localization of the spliced 3’UTR (3’...

Example 1:

Abstract Number: 6610

Title: Abstract 6610: Gut microbiome modulation shapes tumor responses to radiation in oral cavity carcinoma.

DOI: https://doi.org/10.1158/1538-7445.am2026-6610

Abstract Preview: Abstract Tumor associated macrophages (TAMs) are key regulators in the tumor microenvironment (TME) and play an important role in the response to radiation therapy (RT). Therefore, there is a need to better understand the different factors that influence the response to RT. To this end, we used broad-spectrum antibiotics (Abx) to target the microbiome of the gut and oral cavity. We hypothesize tha...

Example 2:

Abstract Number: 2558

Title: Abstract 2558: Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving177Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune response

DOI: https://doi.org/10.1158/1538-7445.am2026-2558

Abstract Preview: Abstract Background: Prostate cancer, a leading cause of cancer-related death in men, is refractory to checkpoint inhibition.1-3 Lutetium-177-labeled PSMA-617 (177Lu-PSMA, Pluvicto) is an FDA-approved radioligand therapy in CRPC. We have shown that a single dose of 177Lu-PSMA is immunomodulatory, and can be safely combined with the PD-1 blockade, pembrolizumab, in a phase 1 clinical trial (NCT0380...

Example 3:

Abstract Number: 7746

Title: Abstract 7746: CEACAM5/6+ cancer cell and IL1B+ macrophage-mediated resistance in anti-PD-1 treated gastric cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-7746

Abstract Preview: Abstract Immune checkpoint blockade therapy has shown limited efficacy in gastric cancer, with most patients developing resistance through mechanisms that remain incompletely defined. Here, we generate a comprehensive single-cell RNA sequencing atlas of 526,583 cells from gastric cancer patients treated with anti-PD-1 plus chemotherapy, analyzing paired pre- and post-treatment samples to capture d...

Example 4:

Abstract Number: 5964

Title: Abstract 5964: Single-cell multi-omics profiling unveils the regulatory mechanisms of small cell lung cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5964

Abstract Preview: Abstract Small cell lung cancer (SCLC) is a highly aggressive lung cancer with an extremely poor prognosis. The mechanisms underlying its tumor progression and therapeutic strategies remain poorly understood. To address this clinical challenge, we utilized single-cell ATAC-RNA multiomic profiling to investigate clonal progression and its regulatory mechanisms. Patient-derived cells (n=73,546) were...

Example 1:

Abstract Number: 6470

Title: Abstract 6470: Spatial remodeling of the tumor microenvironment by IL-18-armored CD19 CAR T cells is associated with durable remission in relapsed or refractory lymphoma

DOI: https://doi.org/10.1158/1538-7445.am2026-6470

Abstract Preview: Abstract Patients with relapsed or refractory B-cell lymphoma who experience disease progression after CD19-directed CAR T-cell therapy have poor outcomes and few effective treatment options. Subsequent therapies provide only modest benefit, with complete remission (CR) rates near 20% and limited durability. huCART19-IL18, an IL-18-secreting CD19 CAR T-cell product, produced an overall response ra...

Example 2:

Abstract Number: 2341

Title: Abstract 2341: Using geospatial methods to analyze associations of neighborhood change on breast cancer mortality in Maryland, 2000-2019.

DOI: https://doi.org/10.1158/1538-7445.am2026-2341

Abstract Preview: Abstract Purpose: To examine whether neighborhood change status (declining, stable, or upgrading) is associated with the risk of breast cancer (BC)-specific mortality. Background: Neighborhood-level social determinants of health are associated with BC mortality, but few studies have investigated how dynamic neighborhood conditions over time and geography (i.e., neighborhood trajectories) can modul...

Example 3:

Abstract Number: 7757

Title: Abstract 7757: Investigating the mechanisms underlying regulatory T cell dysfunction in ICI-induced colitis

DOI: https://doi.org/10.1158/1538-7445.am2026-7757

Abstract Preview: Abstract Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can trigger immune-related adverse events such as colitis. The mechanisms driving these toxicities remain poorly understood. In this study, we analyzed colon biopsies from a patient cohort with ICI-induced colitis using integrated single-cell RNA sequencing and paired spatial transcriptomics and proteomics to defin...

Example 4:

Abstract Number: 6051

Title: Abstract 6051: Pancreatic tumor expressed growth factors activate a neural-like program in human fibroblasts which is associated with poor prognosis

DOI: https://doi.org/10.1158/1538-7445.am2026-6051

Abstract Preview: Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, with a 5-year survival of less than 14%. The tumor microenvironment (TME) plays a central role in PDAC progression and is composed primarily of cancer-associated fibroblasts (CAFs), together with smaller populations of tumor, nerve, and immune cells. Recently, a population of stromal cells exhibiting a neural-l...

Example 1:

Abstract Number: 6394

Title: Abstract 6394: Ferroptosis amplified by a tumor-targeted artesunate nano-derivative for effective colon cancer treatment.

DOI: https://doi.org/10.1158/1538-7445.am2026-6394

Abstract Preview: Abstract Background: Artesunate (ART), a proven antimalarial drug, is promising but has limited antitumor activity because of its poor stability, low potency, and lack of tumor selectivity. While its effect is linked to ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, clinical translation in oncology requires enhanced drug delivery and targeting. We hypothesized that...

Example 2:

Abstract Number: 2563

Title: Abstract 2563: mTOR inhibition augments antitumor immune response by reprogramming the TP53 -mutant, immune-cold HNSCC tumor microenvironment

DOI: https://doi.org/10.1158/1538-7445.am2026-2563

Abstract Preview: Abstract Head and neck squamous cell carcinoma (HNSCC) with TP53 mutations presents significant therapeutic challenges, characterized by high recurrence rates and treatment resistance. Using a TP53-mutant, PD-1 resistant syngeneic mouse flank tumor model, we investigated the immunomodulatory effects of mTOR inhibition (mTORi) followed by comprehensive bulk RNA sequencing analysis. Our transcriptom...

Example 3:

Abstract Number: 7857

Title: Abstract 7857: Multi-modal real-world data uncovers predictors of clinical response to TOP1i and optimizes ADC strategies in colorectal cancer.

DOI: https://doi.org/10.1158/1538-7445.am2026-7857

Abstract Preview: Abstract Real-world data (RWD) encompassing diverse treatment regimens offers a valuable opportunity to identify predictive biomarkers of response and resistance across broad patient populations. Although data from clinical trials with antibody-drug conjugate (ADC) therapies remains limited, analysis of large standard-of-care cohorts offers valuable insight into chemotherapy resistance. For exampl...

Example 4:

Abstract Number: 5551

Title: Abstract 5551: MHC class II targeted immunotherapy in the treatment of pancreatic cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5551

Abstract Preview: Abstract Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumor types, claiming approximately 50,000 lives per year in the United States and carrying a 5-year overall survival rate of only 13%. While immunotherapy has revolutionized therapy for certain cancer types, this has not been the case for PDAC, where there have been zero immunotherapy approvals. This is attribu...

Example 1:

Abstract Number: 6604

Title: Abstract 6604: Aurora kinase B inhibition enhances radiation response and activates type 1 interferon signaling in triple-negative breast cancer.

DOI: https://doi.org/10.1158/1538-7445.am2026-6604

Abstract Preview: Abstract Purpose: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted therapies and poor response to radiotherapy1. Aurora kinase B (AURKB), a key regulator of chromosomal segregation during mitosis, is overexpressed in TNBC and correlates with poor recurrence-free survival following radiation2. Because radiation-induced DNA damage can promote innate immune activati...

Example 2:

Abstract Number: 2577

Title: Abstract 2577: Free and encapsulated tunicamycin significantly enhances the suppression of PD-L1 by gemcitabine through blocking K-RasG12D expression in pancreatic ductal adenocarcinoma cells

DOI: https://doi.org/10.1158/1538-7445.am2026-2577

Abstract Preview: Abstract Pancreatic ductal adenocarcinoma (PDAC) remains one of the leading causes of cancer mortality worldwide, including among U.S. Veterans, and it is expected to become the second leading cause by 2040. The standard treatment options include surgical resection (when possible), chemotherapy, targeted therapy, immunotherapy, and radiation therapy. These treatments can be administered individual...

Example 3:

Abstract Number: 7875

Title: Abstract 7875: Eflornithine and venetoclax combination therapy: Targeting senescence to induce apoptosis in neuroblastoma

DOI: https://doi.org/10.1158/1538-7445.am2026-7875

Abstract Preview: Abstract High-risk neuroblastoma (HRNB) is difficult to cure due to relapses and limited therapeutic durability. Eflornithine, an inhibitor of ornithine decarboxylase, inhibits polyamine synthesis and is clinically effective in preventing HRNB recurrence. Eflornithine induces a stable senescent phenotype that suppresses proliferation. Eliminating these senescent HRNB cells is of therapeutic intere...

Example 4:

Abstract Number: 5755

Title: Abstract 5755: MTORC1/2 inhibition enhances STX-478, a PIK3CA H1047R mutant inhibitor, in PIK3CA H1047R mutant colorectal cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5755

Abstract Preview: Abstract Background: STX-478, a PIK3CA mutant selective inhibitor, that we have previously shown to have promise in treating PIK3CAH1047R mutant colorectal cancer (CRC) models. A high throughput drug screen was performed and identified AZD2014, an MTORC1/2 inhibitor, to have enhanced response with STX-478. Here, we examine the combination of PI3K inhibition with MTORC1/2 inhibition in PIK3CAH1047R...

Example 1:

Abstract Number: 6060

Title: Abstract 6060: Patient-derived models of primary breast cancer for preclinical evaluation of neoadjuvant therapies

DOI: https://doi.org/10.1158/1538-7445.am2026-6060

Abstract Preview: Abstract Targeted therapies are important for invasive breast cancer (IBC) treatment but are generally not standard-of-care in the neoadjuvant setting. To identify therapies with the potential to improve neoadjuvant treatment response, it is essential to develop patient-derived preclinical models that faithfully reflect the diversity of primary IBC subtypes in patients. Here, we collected data of ...

Example 2:

Abstract Number: 2280

Title: Abstract 2280: Ligand-activated AR promotes the survival of endocrine therapy-responsive ER+ breast cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-2280

Abstract Preview: Abstract Giredestrant, a next-generation oral selective ERα degrader (SERD), is a potent and full antagonist that recently demonstrated statistically significant and clinically meaningful improvement in progression free survival (PFS) in the phase III evERA Breast Cancer trial (NCT05306340). Given its potent ER antagonism, giredestrant is currently under evaluation in multiple clinical studies, in...

Example 3:

Abstract Number: 7730

Title: Abstract 7730: A novel ultra-sensitive qPCR-based liquid biopsy assay: ESR1 mutation detection in peripheral plasma derived cfDNA

DOI: https://doi.org/10.1158/1538-7445.am2026-7730

Abstract Preview: Abstract Background: ESR1 mutations are a leading cause of acquired resistance to endocrine therapy in HR+/HER2- metastatic breast cancer (mBC). Monitoring of ESR1 mutations’ dynamic accumulations is critical for patients to quickly switch to effective selective estrogen receptor degrader (SERD) treatment. Therefore, a rapid and cost-effective assay for ESR1 mutations status monitoring is in urgen...

Example 4:

Abstract Number: 5225

Title: Abstract 5225: Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment

DOI: https://doi.org/10.1158/1538-7445.am2026-5225

Abstract Preview: Abstract Introduction: Breast cancer accounts for about one-third of all new female cancer diagnoses and remains the second leading cause of cancer-related mortality among women. Aromatase inhibitors (AIs) are a standard therapy for postmenopausal women with hormone receptor-positive breast cancer, improving disease-free survival compared to tamoxifen. However, prolonged AI use is linked to increa...

Example 1:

Abstract Number: 6654

Title: Abstract 6654: Assessing skin cancer risk in systemic sclerosis patients with organ transplantation: A cohort study.

DOI: https://doi.org/10.1158/1538-7445.am2026-6654

Abstract Preview: Abstract Systemic sclerosis (SSc) is an autoimmune condition characterized by fibrosis of the skin and organs. Cancer is a well-known association of SSc, with a higher incidence in men, and with particular evidence of elevated lung, breast, and melanoma incidence. In addition, non-melanoma skin cancer (NMSC) has been reported to have increased incidence, with one study showing higher incidence in ...

Example 2:

Abstract Number: 2832

Title: Abstract 2832: Evaluation of Natural Killer cells’ contribution to Enhertu toxicity in breast cancer patient derived xenograft-derived 3D models

DOI: https://doi.org/10.1158/1538-7445.am2026-2832

Abstract Preview: Abstract Evaluating the impact of natural killer (NK) cells on antibody-drug conjugate (ADC) activity is essential for understanding and optimizing treatment efficacy. NK cells play a critical role in mediating antibody-dependent cellular cytotoxicity (ADCC), one of the key mechanisms through which ADCs exert their therapeutic effects. By recognizing and eliminating tumor cells via ADC Fc receptor...

Example 3:

Abstract Number: 7851

Title: Abstract 7851: Early-phase clinical trial referral and outcomes in breast cancer: A prospective screening cohort and a real-world Phase I program experience at Gustave Roussy.

DOI: https://doi.org/10.1158/1538-7445.am2026-7851

Abstract Preview: Abstract Background: Early-phase clinical trials are increasingly relevant for metastatic breast cancer, but referral timing and benefit remain insufficiently documented. Methods: We analyzed two complementary cohorts. The first comprised 231 consecutive metastatic breast cancer patients prospectively screened for early-phase trial consideration at Gustave Roussy. The second included all breast ca...

Example 4:

Abstract Number: 5697

Title: Abstract 5697: EZH2 inhibition upregulates GD2 to enhance anti-GD2 immunotherapy in Ewing sarcoma

DOI: https://doi.org/10.1158/1538-7445.am2026-5697

Abstract Preview: Abstract Introduction: Ewing sarcoma (ES) is a rare and aggressive malignancy of the bones and soft tissue for which substantial improvements in treatment options are desperately needed. ES cells heterogeneously express GD2, a surface marker for which there are targeted immunotherapies that are effective in other pediatric malignancies. The use of EZH2 inhibitors has been reported to increase expr...

Example 1:

Abstract Number: 6211

Title: Abstract 6211: AI-guided spatial multi-omics integration reveals immune and stromal heterogeneity underlying population disparities in prostate cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-6211

Abstract Preview: Abstract Prostate cancer disproportionately affects African American (AA) men, who experience higher incidence and mortality rates than European American (EA) men. The purpose of this study was to develop and apply an artificial intelligence (AI)-based framework to investigate biological mechanisms contributing to these disparities through spatial characterization of the tumor microenvironment (TM...

Example 2:

Abstract Number: 2394

Title: Abstract 2394: A novel 2+2 IgG-like bispecific antibody-drug conjugate targeting EBV GP220/350 and EGFR for selective treatment of nasopharyngeal carcinoma.

DOI: https://doi.org/10.1158/1538-7445.am2026-2394

Abstract Preview: Abstract Nasopharyngeal carcinoma (NPC) is endemic in East and Southeast Asia, with Epstein-Barr virus (EBV) infection as a primary etiological factor. The EBV envelope glycoprotein GP220/350 is highly expressed on EBV-positive NPC cells, serving as a tumor-specific antigen. Epidermal growth factor receptor (EGFR) is also overexpressed in >80% of NPC cases and is a validated therapeutic tar...

Example 3:

Abstract Number: 7748

Title: Abstract 7748: Immune-related RNA-seq biomarker-based clustering reveals heterogeneous immunotherapy responses and guides subtype-specific strategies in metastatic NSCLC

DOI: https://doi.org/10.1158/1538-7445.am2026-7748

Abstract Preview: Abstract Metastatic non-small cell lung cancer (mNSCLC) represents a highly heterogeneous disease with variable clinical outcomes under first-line immunotherapy plus chemotherapy. To better understand immune landscape features associated with heterogeneous response to immunotherapy, we performed biomarker-driven RNA-seq molecular clustering using known immune-related markers TIGIT, FOXP3, CD274 (P...

Example 4:

Abstract Number: 5349

Title: Abstract 5349: Refining tumor mutational burden as a predictive biomarker for pembrolizumab: A real-world analysis of 1,899 Japanese patients.

DOI: https://doi.org/10.1158/1538-7445.am2026-5349

Abstract Preview: Abstract Tumor mutational burden (TMB) is a key biomarker for predicting the response to immune checkpoint inhibitors (ICIs). However, its predictive accuracy in real-world clinical practice, particularly in Asian populations, remains inadequately evaluated. We addressed this issue by analyzing real-world data from 63,952 patients registered in the Center for Cancer Genomics and Advanced Therapeut...

Example 1:

Abstract Number: 6831

Title: Abstract 6831: Virtual clinical trials of BMP4 differentiation therapy.

DOI: https://doi.org/10.1158/1538-7445.am2026-6831

Abstract Preview: Abstract Glioma stem cells (GSCs) are considered a major driver of glioblastoma (GBM) progression and are highly resistant to standard cytotoxic treatments. BMP4 has been shown to promote GSC differentiation, enhance radiosensitivity, slow tumor growth, and extend survival in animal models. Despite this promise, BMP4 has yet to achieve clinical impact, owing largely to heterogeneous and nonlinear ...

Example 2:

Abstract Number: 2918

Title: Abstract 2918: Agonist activation of RIG-I+tumor associated macrophages enhances anti-tumor immunity and therapeutic response in glioblastoma

DOI: https://doi.org/10.1158/1538-7445.am2026-2918

Abstract Preview: Abstract Glioblastoma (GBM), the most frequent and aggressive primary tumor of the brain, escapes all standard-of-care treatments that are provided after resection, including chemotherapy, radiotherapy or immunotherapy. The GBM tumor microenvironment is regulated by immunosuppressive mechanisms of the innate immune system, thereby contributing to the lack of anti-tumor adaptive immunity. We found ...

Example 3:

Abstract Number: 7856

Title: Abstract 7856: Prevalence and association of clonal hematopoiesis with cardiovascular health in patients of the Avera sequencing and analytics protocol (ASAP) Study.

DOI: https://doi.org/10.1158/1538-7445.am2026-7856

Abstract Preview: Abstract Introduction: Clonal Hematopoiesis (CH) refers to age-associated somatic mutations in hematopoietic stem cells. CH may be incidentally discovered in oncology patients via next-generation sequencing. Cancer therapies such as cytotoxic chemotherapy and radiation can accelerate the development or expansion of CH, particularly in genes associated with therapy-related myeloid neoplasms. Certai...

Example 4:

Abstract Number: 6375

Title: Abstract 6375: Tardigrade Dsup mRNA nanoparticles reduce chemotherapy-induced normal tissue toxicity.

DOI: https://doi.org/10.1158/1538-7445.am2026-6375

Abstract Preview: Abstract Bleomycin is a commonly used chemotherapeutic in the treatment of lymphomas and germ-cell tumors, yet its utility can be restricted by dose-limiting pulmonary toxicity. Bleomycin-induced generation of reactive oxygen species (ROS) causes significant damage to the alveolar epithelium. This leads to alveolar cell death, senescence, and maladaptive crosstalk with stromal cells, ultimately dr...

Example 1:

Abstract Number: 6456

Title: Abstract 6456: Pan-tumor investigation of peripheral biomarkers of excellent response to anti-PD(L)1-based therapy

DOI: https://doi.org/10.1158/1538-7445.am2026-6456

Abstract Preview: Abstract Background: Immune checkpoint inhibitors (ICIs) have transformed contemporary cancer care, yet few patients experience objective responses. There is a need for novel peripheral biomarkers that can not only identify patients likely to respond but also distinguish those with excellent, durable benefit to enable improved patient selection, therapeutic monitoring, and target discovery. Method...

Example 2:

Abstract Number: 2513

Title: Abstract 2513: Exploring Ziziphus jujuba phytochemicals against oral cancer: Network-based profiling and molecular dynamics analyses

DOI: https://doi.org/10.1158/1538-7445.am2026-2513

Abstract Preview: Abstract Oral cancer remains a major global health challenge due to its complex molecular heterogeneity, limited therapeutic efficacy, and high recurrence rate. This study aimed to identify potential multi-target natural therapeutics derived from Ziziphus jujuba using an integrative computational approach. Network pharmacology was employed to map phytochemical-target interactions relevant to oral ...

Example 3:

Abstract Number: 7834

Title: Abstract 7834: DNA methylation: A highly accurate biomarker for treatment monitoring - A retrospective case study using cfDNA methylation and machine learning in breast cancer patients.

DOI: https://doi.org/10.1158/1538-7445.am2026-7834

Abstract Preview: Abstract DNA methylation plays a critical role in gene regulation and maintaining genomic stability. Abnormal DNA methylation patterns are common in breast cancer and relate to tumor growth and resistance to therapy. Liquid biopsies, especially analyzing cell-free DNA (cfDNA) in plasma, offer a minimally invasive way to monitor tumor-specific molecular changes in real time. This study evaluates th...

Example 4:

Abstract Number: 5548

Title: Abstract 5548: Unbiased discovery of novel macrophage-activating immunotherapies for ALK+ non-small cell lung cancer

DOI: https://doi.org/10.1158/1538-7445.am2026-5548

Abstract Preview: Abstract Non-small cell lung cancer (NSCLC) represents ∼85% of all lung cancer cases and remains one of the leading causes of cancer-related mortality in the United States. Approximately 3-7% of NSCLC patients harbor ALK rearrangements, most commonly the EML4-ALK fusion. Although ALK+ tumors initially respond well to ALK tyrosine kinase inhibitors (TKIs), patients still develop resistance. Lorlati...